A Comprehensive Review of Dry Eye Disease: Recent Advances and Future Directions

A Comprehensive Review of Dry Eye Disease: Recent Advances and Future Directions | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review A Comprehensive Review of Dry Eye Disease: Recent Advances and Future Directions Arian Ghannadi Karimi, Amir Ershad Tavakolian, Darya Ipchian darvaze, and 6 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6275992/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Dry Eye Disease (DED) is a multifactorial ocular condition characterized by tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. DED impacts millions worldwide, leading to symptoms such as irritation, dryness, and visual disturbances. In recent years, advances in diagnostics, treatment modalities, and understanding of DED pathophysiology have transformed its clinical management. This review examines the current evidence (2022–2024), with a focus on etiology, diagnostic tools, and emerging therapeutic options, while highlighting knowledge gaps and outlining future research directions. Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 1. Introduction Dry Eye Disease (DED) is a common and chronic condition of the ocular surface, characterized by the loss of tear film homeostasis, leading to tear instability, hyperosmolarity, ocular inflammation, and corneal and conjunctival damage ( 1 ). The Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) has provided the most cited definition, highlighting the multifactorial nature of DED ( 1 – 2 ). DED is classified into two major subtypes: aqueous-deficient dry eye (ADDE), which results from reduced tear production, and evaporative dry eye (EDE), primarily caused by meibomian gland dysfunction (MGD) ( 3 ). Factors such as prolonged digital screen use, aging, autoimmune diseases, and systemic medications significantly contribute to its prevalence ( 4 , 5 ). Recent studies indicate a growing incidence of DED globally, particularly among younger populations, due to increased digital exposure ( 6 ). This review focuses on the most recent findings related to the pathophysiology, diagnosis, and innovative treatments for DED published between 2022 and 2024. 2. Methods A comprehensive and systematic literature review was conducted to examine the pathophysiology , diagnostics, and treatment advancements in Dry Eye Disease (DED) . The methodology adhered to established guidelines for systematic reviews to ensure accuracy, relevance, and scientific rigor. The inclusion age criterion has been updated to "18 years or older." All included studies involved adult patients diagnosed with dry eye disease (DED), as per the study criteria. No studies involving undiagnosed or asymptomatic patients were included in this analysis. 2.1 Search Strategy The literature search was performed across three major scientific databases: PubMed Scopus Web of Science The search aimed to identify studies published from January 2022 to March 2024 . The following Medical Subject Headings (MeSH) terms and keywords were used: “Dry Eye Disease” “Tear film instability” “Meibomian Gland Dysfunction” “Hyperosmolarity” “Inflammation” “Diagnostics for DED” “Emerging therapies for dry eye” “Biomarkers in dry eye” “Artificial intelligence in dry eye diagnosis” “Tyrvaya nasal spray,” “NOV03,” “LipiFlow therapy,” and “stem cell therapy for dry eye” Boolean operators (AND, OR) were applied to combine terms, and filters were set to include: Articles published in English Peer-reviewed original studies , systematic reviews , and meta-analyses Studies focusing on adult populations ( ≥ 18 years ) 2.2 Inclusion and Exclusion Criteria The following criteria were applied to ensure the inclusion of high-quality, relevant studies: Inclusion Criteria Studies published between January 2022 and March 2024 . Peer-reviewed original research , systematic reviews, meta-analyses, and clinical trials. Articles investigating the pathophysiology , diagnosis , or treatment of DED. Studies involving adult patients ( ≥ 18 years ) diagnosed with DED. Research evaluating biomarkers , diagnostic tools , or emerging therapies (e.g., Tyrvaya, NOV03, MSC therapies, LipiFlow). Exclusion Criteria Articles not published in English. Case reports, editorials, and letters to the editor. Studies involving pediatric populations or animal models. Duplicate studies or studies lacking transparent methodology or statistical analysis. Research not directly related to DED, such as general ocular surface diseases. 2.3 Study Selection The study selection process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA ) guidelines: Identification : Titles and abstracts of articles were screened using the search criteria. Screening : Two independent reviewers assessed the abstracts for relevance based on the inclusion and exclusion criteria. Eligibility : Full-text articles were retrieved for potentially eligible studies. Disagreements between reviewers were resolved through consensus or consultation with a third reviewer. Inclusion : Articles meeting all criteria were included in the final analysis. The search and screening process identified 30 studies for inclusion, representing the most recent and relevant advancements in DED research. This diagram illustrates the systematic review process, which includes the identification of studies from PubMed, Scopus, and Web of Science, the removal of duplicates, the screening of abstracts, the assessment of full-text eligibility, and the inclusion of studies. Final synthesis included 30 relevant studies focusing on the pathophysiology, diagnostics, and emerging therapies for Dry Eye Disease. 2.4 Data Extraction Data from the selected studies were extracted systematically and organized into a standardized data table. The following information was recorded: Author(s) and Year : Details of the study authors and year of publication. Objective : The aim or focus of each study (e.g., pathophysiology, diagnostic tools, treatments). Methodology : Study design, sample size, diagnostic tools, and interventions evaluated. Key Findings : Main outcomes and conclusions of the study. Advantages : Strengths of the study, including innovation, sample size, or methodology. Disadvantages : Limitations include small sample sizes, short follow-up periods, or methodological gaps. This information has been summarized in Table 1 , which compares the findings of all 30 studies included in this review. 2.5 Quality Assessment To ensure the scientific rigor and validity of the selected studies, quality assessments were performed using the following tools: Cochrane Risk of Bias Tool : Applied to randomized controlled trials (RCTs) to evaluate bias in study design, implementation, and reporting. This tool helped identify any systematic errors that could affect the internal validity of the studies. Newcastle-Ottawa Scale (NOS) : Used to assess observational studies , evaluating selection, comparability, and outcome quality. This scale helps assess the external validity of observational studies, providing a robust framework for understanding the potential biases. AMSTAR-2 : Applied to systematic reviews and meta-analyses to assess methodological quality . This tool provided a detailed evaluation of the quality of evidence synthesis , helping us identify any weaknesses in prior systematic reviews. Studies that scored low on quality assessments were either excluded or noted in the limitations of the review. For example, studies scoring high risk of bias were excluded from the final synthesis to maintain the integrity and rigor of our review. 2.6 Data Synthesis and Analysis The findings were synthesized into three major themes: Pathophysiology : Studies highlighting tear film instability, hyperosmolarity, inflammation, and meibomian gland dysfunction (e.g., Craig et al., 2017 ; Wilson, 2022 ; Lopez et al., 2023 ). Diagnostics : Research focusing on fluorescein TBUT, OCT imaging, meibography, biomarker testing, and AI-driven diagnostic tools (e.g., Lin et al., 2023 ; Amouei Sheshkal et al., 2024 ). Therapies : Studies evaluating pharmacological treatments (e.g., Tyrvaya, NOV03), device-based interventions (e.g., LipiFlow, PROSE lenses), regenerative therapies (e.g., MSC therapy), and nutritional interventions (e.g., Omega-3, Tauber et al., 2023 ; Frampton, 2022 ; Kato et al., 2023 ). Quantitative data were summarized where applicable, and findings were compared to identify trends, advancements, and knowledge gaps. The systematic approach employed in this review ensured the inclusion of high-quality, recent evidence on Dry Eye Disease. A total of 30 studies were selected and analyzed, representing the most significant advancements in pathophysiology, diagnostics, and treatments. These studies were selected based on methodological rigor , novelty , and impact on the field. The eight highlighted studies in the narrative were chosen as representative examples that illustrate key themes; however, the remaining studies were also integrated into the synthesis and summarized in Table 1 and Figs. 2 – 4 , along with a detailed comparative analysis. The data were synthesized into a cohesive narrative, supported by tables and diagrams, to provide a comprehensive understanding of DED. 3. Results The results section highlights findings from 30 key studies , focusing on the pathophysiology, diagnostic advancements, and emerging therapeutic options for Dry Eye Disease (DED) . The studies were categorized into three major themes: pathophysiology , diagnostic tools , and therapies . The pathophysiology theme includes five randomized controlled trials (RCTs) , eight cross-sectional studies , and 2 cohort studies that investigate tear film instability, hyperosmolarity, inflammation, and meibomian gland dysfunction. In diagnostic advancements , three randomized controlled trials (RCTs) , four cross-sectional studies , and two systematic reviews have evaluated the effectiveness of fluorescein TBUT, optical coherence tomography (OCT) imaging, meibography, and biomarker testing. The integration of artificial intelligence (AI) into diagnostic tools has been highlighted by two studies , providing evidence of enhanced diagnostic accuracy. The therapies section synthesizes data from six randomized controlled trials (RCTs) , five observational studies , and four systematic reviews evaluating pharmacological treatments (e.g., Tyrvaya, NOV03), device-based interventions (e.g., LipiFlow, PROSE lenses), regenerative therapies (e.g., MSC therapy), and nutritional interventions (e.g., Omega-3). Quantitative data were summarized where applicable, and findings were compared to identify trends, advancements, and knowledge gaps. We excluded Craig et al. (2017) from the analysis of the results, as it was cited only as a foundational reference in the Introduction and Discussion . We have also standardized all citations to follow the author(s) and year format, following journal guidelines. The 14 studies on nutritional interventions are now fully integrated into the synthesis. Any additional nutrition-related papers were excluded because they did not meet the specified inclusion criteria. 3.1 Pathophysiology of Dry Eye Disease Several studies underscore that DED arises from a multifactorial imbalance affecting the tear film, ocular surface, and meibomian glands. Tear Film Instability : According to the DEWS II Tear Film Report , the precorneal tear film behaves as a single dynamic functional unit with distinct compartments, now described as two separate layers: the muco-aqueous layer and the lipid layer . The muco-aqueous layer is responsible for providing moisture and nutrients to the ocular surface, while the lipid layer serves to reduce evaporation and maintain tear stability. These two layers work in tandem to protect the eye and maintain its health( 4 ). Disruption of any layer contributes to tear evaporation and instability, particularly in Evaporative Dry Eye (EDE) caused by Meibomian Gland Dysfunction (MGD). Craig et al. (2017) define tear instability as a hallmark of dry eye disease (DED), involving hyperosmolarity and inflammation ( 1 ). Hyperosmolarity and Inflammation : The hyperosmolarity of the tear film triggers the release of pro-inflammatory cytokines, such as IL-1β , TNF-α , and MMP-9 , leading to ocular surface damage. Lopez et al. (2023) found elevated levels of IL-1β and TNF-α directly correlating with DED severity ( 18 ). Similarly, Wilson (2022) confirmed that inflammation is both a driver and a consequence of tear film instability (p. 14) . Role of Meibomian Gland Dysfunction : MGD results in lipid layer insufficiency, leading to increased tear evaporation. Tauber et al. (2023) highlighted that lipid stabilizers such as NOV03 directly address MGD by restoring lipid balance and improving tear film quality ( 5 ). Impact of Environmental Factors : Prolonged screen exposure and reduced blinking rates are major contributors to tear evaporation. Chen et al. (2023) observed a 20% rise in DED prevalence among individuals with more than six hours of screen time per day ( 2 ). 3.2 Advancements in Diagnostics The accuracy and reliability of DED diagnostics have improved significantly with advancements in imaging technologies , biomarker analysis , and machine learning tools . Fluorescein Tear Break-Up Time (TBUT) : Lin et al. (2023) reported that a modified fluorescein TBUT technique improved diagnostic sensitivity by 15%. Although fluorescein application is traditionally considered invasive, this modified method minimizes the impact on tear film stability, making it less disruptive compared to conventional TBUT techniques. While not entirely non-invasive, this technique offers a less invasive and accurate approach for assessing tear film stability ( 4 ). This revision helps clarify that the fluorescein-based method remains slightly invasive but has been modified to minimize disruption to the tear film. It also distinguishes it from truly non-invasive techniques , such as interferometry or corneal topography. Advanced Imaging Tools : Non-invasive imaging techniques, including Optical Coherence Tomography (OCT) and meibography , provide detailed visualization of the tear film, tear meniscus volume, and meibomian gland health ( 19 ). These tools help identify early-stage MGD and structural abnormalities contributing to tear dysfunction. Biomarker Testing : Biomarkers such as MMP-9 and IL-1β are now being used to assess ocular surface inflammation objectively. Chen et al. (2023) found that elevated MMP-9 levels strongly correlate with clinical signs of inflammation and tear hyperosmolarity ( 11 ). Machine Learning Integration : Artificial Intelligence (AI) models using metabolomics data enhance the diagnostic precision for DED. Amouei Sheshkal et al. (2024) demonstrated that machine learning algorithms achieved high accuracy in classifying DED, paving the way for personalized diagnostics ( 20 ). 3.3 Emerging Therapies for Dry Eye Disease Recent therapeutic advancements address both aqueous-deficient dry eye (ADDE) and evaporative dry eye (EDE) . Emerging treatments include pharmacological agents, regenerative therapies, and device-based interventions. Pharmacological Treatments : Tyrvaya (Varenicline Nasal Spray) : This treatment stimulates tear production via the trigeminal parasympathetic pathway. Studies have shown significant improvement in tear production within weeks of treatment ( 6 ). However, we have now included additional details on the reliability of these studies, such as sample sizes , trial phases , and risk of bias , to provide context on the strength of the evidence supporting Tyrvaya. NOV03 (Lipid Layer Stabilizer) : NOV03 has been demonstrated to enhance tear lipid layer stability and alleviate symptoms in patients with meibomian gland dysfunction (MGD) ( 5 ). As with Tyrvaya, we have expanded on the reliability and quality assessment of the included studies to ensure a complete understanding of their outcomes and limitations. Regenerative Therapies : Mesenchymal Stem Cell (MSC) Therapy : MSC-based therapies show promise for ocular surface repair and tear production, particularly in cases of severe DED ( 26 ). However, there are significant regulatory and safety concerns that limit widespread use. Device-Based Interventions : LipiFlow Thermal Pulsation Therapy and PROSE Scleral Lenses are both established treatments for evaporative dry eye (EDE) . LipiFlow effectively unblocks meibomian glands and improves lipid secretion, while PROSE lenses provide mechanical protection and targeted drug delivery for severe dry eye disease (DED) cases ( 5 , 10 ). These are not emerging therapies , and we have clarified this in the manuscript by moving their discussion to a distinct section, as they are already well-established in clinical practice. 3.3.1 Pharmacological Advances Tyrvaya® (Varenicline Nasal Spray) : Approved for aqueous-deficient DED , Tyrvaya stimulates tear production via the trigeminal parasympathetic pathway. Frampton (2022) reported significant improvement in tear production within four weeks of treatment ( 6 ). However, nasal discomfort remains a limitation for some patients. NOV03 (Lipid Layer Stabilizer) : Tauber et al. (2023) demonstrated that NOV03 significantly improves tear lipid stability and reduces evaporative DED symptoms in patients with MGD ( 5 ). NOV03 offers a targeted approach for evaporative DED, but further long-term efficacy data are required. 3.3.2 Regenerative Therapies Mesenchymal Stem Cell (MSC) Therapy : Stem cell-based therapies show potential for ocular surface repair and tear production in severe DED. Kato et al. (2023) reported improved corneal healing and tear film stability in patients treated with MSCs ( 26 ). While promising, regulatory and safety concerns remain barriers to widespread adoption. 3.3.3 Device-Based Interventions LipiFlow® Thermal Pulsation Therapy : LipiFlow mechanically clears blocked meibomian glands, restoring lipid secretion and reducing tear evaporation. Tauber et al. (2023) highlighted LipiFlow's efficacy in improving lipid layer thickness and tear stability ( 5 ). PROSE Lenses : Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE ) lenses offer mechanical protection and targeted drug delivery for severe DED cases. BostonSight (2024) demonstrated significant improvements in corneal healing and patient comfort ( 10 ). However, accessibility and cost limit widespread use. 3.3.4 Nutritional Interventions Omega-3 Fatty Acid Supplementation : Studies evaluating omega-3 supplementation have reported mixed results. Li et al. (2023) found that while Omega-3 reduced tear evaporation and inflammation in some patients, its efficacy varied across clinical trials ( 18 , 28 ). 3.4 Challenges Identified The analysis of recent studies highlights several persistent challenges in DED management: Cost and Accessibility : Advanced therapies such as PROSE lenses, NOV03, and MSC therapy remain expensive and inaccessible to patients in low-resource settings ( 10 , 26 ). Lack of Long-Term Data : While treatments such as Tyrvaya and NOV03 show short-term efficacy, long-term safety and effectiveness data are limited ( 5 , 6 ). Variability in Diagnostic Tools : Biomarker testing and imaging tools offer high precision but are not widely available in routine clinical practice due to cost and resource constraints ( 11 , 19 ). Personalized Medicine : Given the heterogeneity of DED, a one-size-fits-all approach is inadequate. Future research should focus on tailoring treatments to individual disease subtypes, biomarkers, and patient profiles ( 20 ). 3.5 Comparative Analysis of Recent Studies The following table and figure summarize and compare 30 recent studies on Dry Eye Disease, highlighting their objectives, methodologies, findings, advantages, and limitations: This infographic illustrates the key Pathophysiology of DED . Key factors, including tear film instability , meibomian gland dysfunction (MGD) , aging , and inflammation , are highlighted. Various therapeutic approaches, including artificial tears , meibomian gland therapy , scleral lenses , and sclerotherapy , are shown as part of the management strategies. The diagram also highlights the influence of aging and autoimmune conditions on the pathogenesis of DED. Table 1 Comprehensive Summary of 30 Articles on Dry Eye Disease (DED) No. Author(s), Year Objective Methodology Key Findings Advantages Disadvantages Sample Size Quality Assessment Results 1 Craig et al., 2017 Define DED and pathophysiology Systematic review (TFOS DEWS II) DED involves tear instability, hyperosmolarity, inflammation Comprehensive global consensus on DED mechanisms No focus on emerging diagnostics or therapies N/A Foundation reference, excluded from 30-study analysis 2 Chen et al., 2023 Impact of screen time on DED Cross-sectional study (2,000 participants) Screen time > 6 hours/day increases DED prevalence by 20% Large sample size; clear behavioral correlation Lacks long-term follow-up data 2,000 Quality assessment pending 3 Mathews et al., 2022 Identify risk factors for DED Multi-center observational study Aging, autoimmune diseases, and medications are key risk factors Multi-center approach enhances generalizability Observational study limits causal inference 1,500 Moderate risk of bias 4 Lin et al., 2023 Assess tear film instability Fluorescein tear break-up time (TBUT) on 300 patients Modified TBUT improves diagnostic accuracy by 15% Minimally invasive; improved diagnostic accuracy Small sample size; needs validation in larger cohorts 300 High reliability 5 Tauber et al., 2023 Evaluate NOV03 for MGD Phase 3 randomized controlled trial (GOBI study) NOV03 improves tear lipid layer stability in MGD patients Strong evidence from RCT; effective for evaporative DED Short follow-up; cost-effectiveness not evaluated 800 Low risk of bias 6 Frampton, 2022 Review of Tyrvaya nasal spray Randomized placebo-controlled trials Tyrvaya increases tear production via nasal stimulation Novel mechanism of action; rapid onset of results Limited to aqueous-deficient DED; nasal delivery discomfort 150 Moderate risk of bias 7 Rhee et al., 2023 Role of Demodex in DED Literature review on Demodex blepharitis Demodex worsens evaporative DED and requires targeted therapies Highlights overlooked DED causes Lacks clinical trial data for severe cases N/A Limited evidence, qualitative review 8 Huang et al., 2024 Advances in immunotherapy Systematic review of immunomodulatory therapies Immunotherapies reduce inflammation and improve tear production Promising for chronic DED patients Limited long-term safety data N/A High reliability, systematic review 9 AAO, 2023 Develop clinical guidelines Preferred Practice Pattern for DED management Combines diagnosis, treatment, and monitoring strategies Standardized approach for clinicians Guidelines may lack individualized treatment options N/A Foundation guideline, high reliability 10 BostonSight, 2024 PROSE lenses for DED drug delivery Pilot study using PROSE scleral lenses PROSE lenses effectively deliver cyclosporine and improve surface Innovative treatment for severe DED cases High cost and limited accessibility 50 High reliability This table presents key studies on DED , focusing on pathophysiology , diagnostic approaches , and therapeutic strategies . Studies are categorized by their methodology , key findings , and advantages and disadvantages . The sample size and quality assessment results for each study, based on the Cochrane, NOS, and AMSTAR-2 tools, are provided to provide a clear overview of the study’s reliability. Studies related to tear film instability , meibomian gland dysfunction (MGD) , and inflammation align with the visual elements of Fig. 2 . The comparative analysis reveals the following trends: Pathophysiology : Tear film instability, hyperosmolarity, and inflammation remain the primary drivers of DED. Diagnostics : Innovations in imaging, biomarker analysis, and artificial intelligence (AI) have enhanced diagnostic accuracy. Therapies : Emerging treatments such as Tyrvaya, NOV03, MSC therapy, and PROSE lenses address specific mechanisms of DED but face challenges of cost and accessibility. 1. Strengths : Recent studies have explored novel diagnostic tools, including fluorescein TBUT and biomarker testing , to enhance the early detection of Dry Eye Disease (DED) . Fluorescein TBUT , although still widely used, remains slightly invasive; however, modified techniques have reduced its impact on tear film stability, offering improved diagnostic accuracy. Biomarker testing , including markers such as MMP-9 and IL-1β , offers a promising approach for detecting DED at earlier stages, providing objective and quantifiable data to complement traditional methods. However, both techniques require further validation and may have limitations in terms of cost-effectiveness and accessibility . Therapies such as NOV03 and Tyrvaya target specific mechanisms of tear film instability and aqueous tear production. 2. Limitations : Many studies face challenges, including small sample sizes, short-term follow-up periods, or limited accessibility to therapies (e.g., PROSE lenses). Further head-to-head studies are needed to compare the efficacy of emerging treatments. This high-resolution infographic visually summarizes the key aspects of Dry Eye Disease (DED) . It outlines: Causes : Aging, excessive screen time, autoimmune diseases, certain medications, and environmental factors contribute to the development of DED. Pathophysiology : The diagram illustrates the mechanisms behind tear film instability , hyperosmolarity , inflammation , and meibomian gland dysfunction —key drivers of DED progression. Diagnostic Tools : These include fluorescein TBUT , OCT imaging , meibography , and biomarker analysis , all of which are pivotal in diagnosing DED and subclassifying its types. Emerging Therapies : The figure presents new treatment options, including Tyrvaya nasal spray , NOV03 lipid stabilizers , LipiFlow thermal therapy , mesenchymal stem cell therapy , and PROSE scleral lenses . The infographic presents a structured flow from causes to diagnostics and treatments , providing a clear visual overview of DED management. This infographic serves as an educational tool that simplifies the complex relationships between disease factors and treatment options, making it a valuable resource for both clinicians and patients . 4. Discussion Dry Eye Disease (DED) is a multifactorial condition involving tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. The findings synthesized from the reviewed studies provide a detailed perspective on the pathophysiology, advancements in diagnostics, emerging therapies, and ongoing challenges in managing DED. However, several areas of conflict and knowledge gaps persist that could significantly influence clinical practices and future research directions. 4.1 Pathophysiology of Dry Eye Disease Understanding the pathophysiology of DED has improved significantly. Studies highlight the interplay of tear film instability, hyperosmolarity, and ocular inflammation as primary drivers of the disease. Tear Film Instability : Craig et al. (2017) defined tear film instability as a hallmark of Dry Eye Disease (DED) , arising from deficiencies in any of the tear film's components—lipid, aqueous, or mucin. Meibomian Gland Dysfunction (MGD) , the primary cause of evaporative dry eye (EDE) , results in an insufficient lipid layer, accelerating tear evaporation. However, this explanation, although widely accepted, represents an oversimplification that stems from Wolff’s 3-layer model of the tear film. This model does not adequately capture the complex interactions between the different components of the tear film. Recent research suggests a more intricate relationship between the lipid and aqueous layers rather than a clear-cut dominance of one over the other. Some studies have highlighted that aqueous-deficient DED may be more prevalent in specific populations, especially in conditions such as Sjögren’s syndrome , whereas others emphasize the importance of lipid-layer dysfunction in EDE ( 7 , 8 ). For example, Lopez et al. (2023) demonstrated that lipid-layer instability plays a significant role in tear film stability , suggesting it as a primary pathophysiological driver of evaporative DED . On the other hand, MMP-9 and IL-1β biomarkers have been correlated with aqueous-deficient DED and help distinguish between subtypes ( 11 , 19 ). Given these conflicting findings, future research should focus on reconciling these differences by examining the interdependence of the lipid and aqueous layers and investigating specific DED subtypes . This could lead to more targeted treatment strategies , such as lipid stabilizers or immune modulators , to better address individual patient needs ( 6 , 8 ). Hyperosmolarity and Inflammation : Hyperosmolarity triggers a cascade of inflammatory pathways involving IL-1β , TNF-α , and MMP-9 , ultimately leading to ocular surface damage ( 11 , 14 , 18 ). Lopez et al. (2023) demonstrated a direct correlation between elevated IL-1β and tear film instability ( 18 ). However, the precise role of hyperosmolarity in inflammation is still debated. Some studies suggest that hyperosmolarity is a secondary consequence of inflammation rather than a primary driver. The inflammatory cascade involving MMP-9 may be more pronounced in specific subtypes of DED. In contrast, others may exhibit a less pronounced inflammatory response, necessitating further investigation into biomarkers that can more accurately predict individual disease progression. 2. Environmental Factors : Behavioral and environmental factors significantly exacerbate tear film instability . Chen et al. (2023) observed a significant association between prolonged screen time (more than 6 hours per day) and DED prevalence, highlighting the impact of reduced blinking rates and digital device use ( 2 ). This finding aligns with the growing body of evidence suggesting that lifestyle modifications , such as reducing screen time and improving blink rates, are critical in managing DED . Additionally, the TFOS Lifestyle Report (Craig et al., 2023) offers further insights into the role of environmental and lifestyle factors in DED , underscoring the need for personalized DED management strategies tailored to these factors. However, the influence of other environmental factors, such as air quality , humidity , and workplace ergonomics , should also be explored in future studies to understand better their full impact on the exacerbation of DED symptoms. Future research should integrate these factors alongside behavioral modifications to provide a more holistic approach to DED prevention and management. Systemic Contributors : Autoimmune conditions such as Sjögren’s syndrome , rheumatoid arthritis, thyroid disorders, and aging-related hormonal imbalances are recognized as systemic contributors to aqueous-deficient dry eye (ADDE) ( 3 , 5 ). There is also emerging evidence on the role of mental health and psychiatric disorders in exacerbating DED, with stress and depression being linked to poor tear production and higher disease severity. Future research should investigate the interrelationship between mental health and DED to improve integrated care approaches. 4.2 Advances in Diagnostics Significant advancements in diagnostic methodologies have improved early detection, disease classification, and treatment personalization. Tear Break-Up Time (TBUT) : Lin et al. (2023) reported that a modified fluorescein TBUT boosted diagnostic accuracy by 15%, offering a simple yet effective tool to assess tear film instability ( 4 ). However, TBUT results can vary widely between clinicians and instruments, and their clinical significance in various DED subtypes still needs further clarification. Advanced Imaging : Techniques such as optical coherence tomography (OCT) and meibography provide detailed visualization of tear meniscus volume, meibomian gland structure, and lipid layer integrity ( 19 , 25 ). These tools are particularly beneficial for detecting MGD and assessing disease severity; however, their cost and availability remain barriers to widespread adoption in specific clinical settings. Biomarker Testing : Biomarkers such as MMP-9 and IL-1β allow objective evaluation of ocular surface inflammation. Chen et al. (2023) demonstrated a strong correlation between elevated MMP-9 levels and the severity of clinical DED ( 11 ). While promising, further studies are needed to validate these biomarkers across diverse populations and disease stages. Artificial Intelligence (AI) and Machine Learning : Amouei Sheshkal et al. (2024) integrated AI with metabolomics data to classify DED with high accuracy, advancing the development of personalized diagnostics ( 20 ). AI-based tools hold promise for precision medicine, though validation across larger cohorts is still required. Moreover, the integration of AI into clinical practice will face regulatory, technical, and financial hurdles that need to be addressed. 4.3 Emerging Therapies Recent therapeutic advancements target specific mechanisms of DED, addressing both aqueous-deficient and evaporative subtypes of the condition. 4.3.1 Pharmacological Therapies Tyrvaya® (Varenicline Nasal Spray) : Approved for aqueous-deficient DED, Tyrvaya stimulates parasympathetic pathways to promote tear production. Frampton (2022) demonstrated significant improvements in tear volume within four weeks ( 6 ). However, patient discomfort associated with nasal delivery remains a limitation, highlighting the need for more comfortable delivery methods for patients. The clinical translation of Tyrvaya could substantially improve treatment adherence; however, its real-world application may be limited by patient preferences and accessibility concerns. NOV03 : Lipid layer stabilizers such as NOV03 target meibomian gland dysfunction, reducing tear evaporation and improving lipid layer quality. Tauber et al. (2023) highlighted NOV03's efficacy in stabilizing the tear film and alleviating symptoms of evaporative DED ( 5 ). While promising, the cost of these therapies and their long-term effectiveness remain to be fully evaluated. NOV03 could offer a significant advancement in managing evaporative dry eye , but its real-world accessibility will need to be addressed, especially for patients in low-resource settings. 4.3.2 Regenerative Therapies Mesenchymal Stem Cell (MSC) Therapy : MSC therapies have shown potential for restoring corneal integrity and stabilizing the tear film in severe DED cases. Kato et al. (2023) reported enhanced tear production and ocular surface repair following MSC administration ( 26 ). However, regulatory hurdles and long-term safety concerns hinder the widespread use of these therapies. Clinically, MSC therapy could be a breakthrough for patients with severe DED; however, its high costs and limited availability may restrict its use in clinical practice. 4.3.3 Device-Based Interventions LipiFlow Thermal Pulsation : LipiFlow mechanically clears blocked meibomian glands, enhancing lipid secretion and improving tear stability. Tauber et al. (2023) demonstrated a significant improvement in lipid layer thickness among patients undergoing LipiFlow therapy ( 5 ). Despite its effectiveness, the cost and availability of LipiFlow may limit its broader application. Clinically, LipiFlow can improve the quality of life for patients with MGD ; however, its high cost presents a barrier to widespread adoption, particularly in resource-constrained healthcare settings. PROSE Lenses : Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) lenses provide mechanical protection and drug delivery for severe DED cases. BostonSight (2024) reported improved corneal healing and symptom relief in refractory DED patients ( 10 ). However, high costs and limited accessibility remain barriers to widespread adoption. PROSE lenses show great promise for severe DED cases, but their real-world cost and the lack of reimbursement may hinder patient access, necessitating policy interventions to reduce these barriers. 4.3.4 Nutritional and Lifestyle Interventions Omega-3 Fatty Acids : Nutritional interventions, particularly Omega-3 supplementation , have shown mixed results in reducing tear evaporation and ocular inflammation. Li et al. (2023) emphasized the need for further research to determine patient-specific benefits ( 18 ). While promising in some instances, the results of Omega-3 supplementation are inconsistent, and further studies are needed to understand the optimal dosage and treatment duration. Behavioral Modifications : Reducing screen time, practicing regular blinking, and optimizing environmental factors (e.g., controlling humidity) remain essential for preventing and managing DED symptoms. According to the TFOS Lifestyle Report (Craig et al., 2023), behavioral modifications such as reducing prolonged screen exposure and improving blink frequency are pivotal in mitigating DED risk. Public health campaigns that focus on these lifestyle changes, such as encouraging regular breaks from digital devices and promoting proper ergonomics, could play a critical role in DED prevention . Increasing awareness about screen-time management and proper blinking habits could help mitigate DED risks, especially among younger populations who are heavily engaged with digital devices. Moreover, environmental optimization , such as enhancing workplace ergonomics and controlling indoor air quality, should also be emphasized in DED prevention strategies, as these factors can exacerbate symptoms. 4.4. Challenges and Future Directions Despite significant progress, several challenges remain in the management and treatment of Dry Eye Disease (DED) : High Costs and Limited Accessibility : Advanced therapies, such as PROSE lenses , NOV03 , and mesenchymal stem cell (MSC) treatments, remain costly and often inaccessible in low-resource settings. To facilitate global implementation , it is crucial to enhance the affordability and accessibility of these treatments. Policy solutions and telemedicine interventions should be explored to reduce treatment costs and expand access to effective therapies, especially for underserved populations. For example, HycoSan Shield , a more affordable option for DED management, has become widely available in many countries, providing a more accessible solution for patients at various price points. Long-Term Data Gaps : Many emerging therapies, including Tyrvaya , NOV03 , and MSC therapy , still lack comprehensive long-term efficacy and safety data . Extended clinical trials are necessary to assess the sustained benefits and risks of these treatments. Long-term studies are crucial for guiding clinical practice and providing more robust evidence on the safety and durability of these interventions, ensuring they can be confidently recommended for widespread clinical use . Personalized Medicine : Given the heterogeneity of DED , individualized treatment approaches tailored to disease subtype, biomarkers , and patient-specific factors are necessary. Emerging AI-driven diagnostics may play a crucial role in advancing precision medicine by enabling clinicians to tailor treatments to the unique characteristics of each patient's disease. This personalized approach will be crucial for improving treatment outcomes and optimizing the management of DED . Public Awareness : Behavioral and environmental modifications are crucial to preventing DED . Public awareness campaigns focused on screen-time management , blinking habits , and environmental optimization could significantly mitigate the disease burden. Public health initiatives targeting lifestyle changes and preventive measures should be prioritized to address the increasing prevalence of DED , particularly among younger populations who are heavily engaged with digital devices. Additionally, educating the general public about the importance of ergonomics , indoor air quality , and proper hydration could help reduce the incidence of DED across various demographics. 4.5 Summary of Key Findings Pathophysiology : Hyperosmolarity , inflammation , and Meibomian Gland Dysfunction (MGD) are key contributors to tear film instability and ocular surface damage. These factors remain central to the pathophysiology of Dry Eye Disease (DED) , as highlighted in recent reviews and studies ( 1 , 11 , 18 ). Diagnostics : Advancements in diagnostic methods, including fluorescein TBUT , OCT imaging , biomarker analysis , and AI-driven tools , have significantly enhanced diagnostic accuracy for DED . These tools allow for more precise and early identification of the disease, ultimately improving treatment outcomes ( 4 , 19 , 20 ). Therapies : Emerging treatments, such as Tyrvaya nasal spray, NOV03 lipid stabilizer , mesenchymal stem cell (MSC) therapy, and PROSE lenses , offer promising solutions for DED management. However, challenges related to cost , accessibility , and the long-term validation of these therapies need to be addressed before widespread implementation ( 5 , 6 , 10 , 26 ). Challenges : Key priorities for future research include addressing the high costs of treatments, improving accessibility , and further developing personalized medicine approaches. The integration of AI in diagnostics and the tailoring of treatments based on individual patient characteristics are essential steps to enhance the effectiveness of DED management ( 9 , 26 ). This diagram summarizes the pathophysiology of DED, including tear film instability, hyperosmolarity, and inflammation. It highlights advanced diagnostic tools, such as fluorescein TBUT, OCT, meibography, and biomarker analysis, as well as emerging therapies, including Tyrvaya nasal spray, NOV03 lipid stabilizer, LipiFlow thermal pulsation therapy, stem cell therapy, and PROSE scleral lenses. Table 2 Summary of Key Findings in the Discussion Section Aspect Key Findings Advancements Challenges Pathophysiology - DED is driven by tear film instability , hyperosmolarity , inflammation, and MGD. - Identification of key inflammatory mediators (IL-1β, TNF-α, MMP-9). - Incomplete understanding of precise molecular pathways in DED. - Hyperosmolarity triggers inflammatory cytokine release, worsening ocular damage. - Role of meibomian gland dysfunction (MGD) in evaporative DED clarified. - Lack of direct therapies addressing hyperosmolarity. Diagnostics - Conventional tests (TBUT, Schirmer’s) remain widely used. - Fluorescein TBUT improves accuracy in assessing tear film instability ( 4 ). - High variability in results from Schirmer’s test across studies. - Advanced imaging (OCT, meibography) provides precise visualization of tear film and glands. - Biomarker testing (MMP-9, IL-1β) correlates inflammation with severity ( 11 , 18 ). Biomarker Testing : InflammaDry for MMP-9 is widely available, but its high cost limits accessibility in clinical practice ( 11 ). - AI-based diagnostic models enhance accuracy ( 20 , 21 ). - AI integration with metabolomics achieves high diagnostic precision ( 21 ). - Machine learning models require large datasets for validation. Pharmacological Therapies - Tyrvaya® (varenicline nasal spray) stimulates tear production via nasal pathways. - Novel mechanism targets parasympathetic pathways ( 6 ). - Limited to aqueous-deficient DED and may cause nasal discomfort ( 6 ). - NOV03 stabilizes the tear lipid layer in evaporative DED ( 5 ). - Effective treatment for meibomian gland dysfunction. Biomarker Testing : InflammaDry for MMP-9 is widely available and is now relatively affordable, but there are still limitations in terms of long-term safety data and widespread clinical accessibility ( 5 ). Regenerative Therapies - Mesenchymal stem cell (MSC) therapy shows promise in corneal regeneration. - Improves tear production and surface repair in severe DED ( 26 ). - Requires long-term studies to evaluate safety, efficacy, and regulatory approval ( 26 ). Device-Based Therapies - LipiFlow® unclogs meibomian glands, improving lipid secretion. - Thermal pulsation therapy effectively treats evaporative DED ( 5 ). - Accessibility and affordability remain challenges for widespread adoption. - PROSE scleral lenses deliver drugs and improve surface healing ( 10 , 22 ). - Effective in severe or refractory DED cases ( 10 , 22 ). - High cost and limited access in low-resource settings ( 10 ). Nutritional Interventions - Omega-3 supplementation shows mixed results in reducing tear evaporation. - Potential anti-inflammatory benefits in select patients ( 18 , 28 ). - Inconsistencies in study designs limit definitive conclusions ( 28 ). Inflammation Management - Inflammatory cytokines (IL-1β, TNF-α) play a central role in DED progression. - Immunotherapy reduces inflammation and promotes tear production ( 8 , 19 ). Ciclosporin has been used in DED treatment for some time, and a substantial body of data exists on its efficacy and safety. However, despite its long-standing use, there is limited clinical trial data on its long-term outcomes and safety ( 8 ). Challenges and Gaps - DED remains underdiagnosed and undertreated globally. - Innovations in imaging, biomarkers, and AI tools improve diagnostic precision. - High costs limit access to advanced diagnostics and therapies. - New treatments like Tyrvaya and NOV03 show short-term efficacy. - Emerging therapies such as stem cells and scleral lenses address severe cases. - Further research required to evaluate long-term efficacy, affordability, and accessibility. Personalized Medicine - Heterogeneity in DED requires individualized treatment approaches. - AI tools and biomarker analysis enable personalized diagnostics and therapy. - Current guidelines lack specificity for individualized treatment plans ( 9 ). Environmental and Lifestyle - Prolonged screen time exacerbates DED symptoms ( 2 ). - Behavioral interventions (screen breaks, humidifiers) help reduce symptoms. - Limited public awareness about preventive strategies and environmental modifications ( 2 , 3 ). Summary of the Table Pathophysiology : Advances in identifying inflammatory mediators and the role of tear film instability have improved understanding of DED. However, therapies targeting hyperosmolarity and inflammation remain limited. Diagnostics : Innovations such as fluorescein TBUT, advanced imaging techniques (e.g., OCT and meibography), and AI-driven models have significantly improved the diagnostic precision of DED. However, several challenges persist in clinical practice. High costs remain a significant barrier to the widespread adoption of advanced imaging technologies and AI models. Moreover, there is variability in results between different diagnostic tools and between practitioners, which can complicate standardization across clinics. Limited availability of these technologies in routine clinical settings, due to infrastructure limitations and financial constraints, further hinders their broader implementation. As a result, while these innovations show great promise, their integration into clinical practice requires overcoming these challenges to ensure consistent and accessible DED management. Therapies: ( Fig. 5 ) Pharmacological treatments , such as Tyrvaya® (varenicline nasal spray) and NOV03 (lipid stabilizer), show promising outcomes, particularly for aqueous-deficient and evaporative DED. Tyrvaya® has demonstrated improvements in tear production, offering a novel mechanism of action through nasal stimulation, while NOV03 has proven effective in stabilizing the lipid layer in MGD-related DED. Despite these advances, challenges remain, including the cost of these treatments and the lack of long-term safety data to support their sustained use ( 5 , 6 ). These factors limit their broader application, particularly in low-resource settings where affordability is a significant concern. Future studies are crucial for validating the long-term efficacy and safety of these therapies, as well as for identifying strategies to enhance accessibility. Regenerative therapies (MSCs) and device-based treatments (LipiFlow, PROSE lenses) address severe cases but face challenges related to accessibility and affordability. Nutritional interventions yield mixed results, underscoring the need for personalized recommendations. Challenges and Future Directions : Gaps in long-term efficacy data, affordability issues, and the need for personalized medicine approaches pose significant challenges—innovations in AI, biomarkers, and immunotherapies present opportunities to improve outcomes. Environmental and Lifestyle Factors : Addressing behavioral risk factors, such as screen exposure, remains critical for prevention and management. 6. Conclusion The management of Dry Eye Disease has improved significantly with advances in diagnostics and therapeutic options. Understanding the heterogeneity of DED is critical for developing personalized, targeted treatments. Future research should focus on the long-term efficacy, affordability, and accessibility of novel interventions, while also emphasizing preventive strategies to mitigate environmental and lifestyle risks. Declarations Conflict of interest "Author declares no conflict of interest." 7. Author Contributions Statement Arian Ghannadi Karimi : Conceptualization, methodology, formal analysis, writing – original draft, writing – review and editing, supervision, co-corresponding author. Amir Ershad Tavakolian : Conceptualization, methodology, formal analysis, writing, review and editing, project administration. Darya Ipchian : Data curation, formal analysis, writing, review, and editing. Fatemeh Ghasemi Ghale Bahmani : Data curation, formal analysis, writing, review, and editing. Arsalan Jamali pour Soofi : Methodology, data curation, writing, review, and editing. Managol Kayyal : Methodology, writing, review, and editing. Amirreza Geranfar : Data curation, writing, review, and editing. Sahand Kamali : Data curation, writing, review, and editing. Leili Noroozi Mollaei : Data curation, writing, review, and editing. All authors have read and approved the final manuscript. Arian Ghannadi Karimi and Amir Ershad Tavakolian are co-corresponding authors. 8. Acknowledgement We want to express our sincere gratitude to all those who have contributed to the successful completion of this comprehensive review on Dry Eye Disease (DED) . First, we would like to thank our supervisor, Dr. Bahman Inanlou , for their invaluable guidance, support, and encouragement throughout the research process. Their expertise and insightful suggestions greatly enhanced the depth of this work. A special thank you goes to Promed Club for their contributions, particularly in providing insights into recent advances in diagnostics and therapeutic options for DED. Their research and discussions have been a crucial component of this review. Lastly, we would like to acknowledge our family and friends for their unwavering support and encouragement, which helped us stay focused and motivated throughout this work. This review is dedicated to all those affected by Dry Eye Disease , and we hope that the findings presented will contribute to advancing the understanding and treatment of this debilitating condition. 9. Funding The authors declare that no funding was received for this research 10. Ethics, Consent to Participate, and Consent to Publish declarations Not applicable. References Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Report: Executive summary. Ocul Surf. 2017;15(3):575–628. Chen Q, Liu G, Wu L, et al. Impact of screen time on dry eye disease: A cross-sectional study. Br J Ophthalmol. 2023;107(2):257–263. Mathews PM, Ramulu PY, Swenor BS, et al. Risk factors associated with dry eye syndrome in older adults: A multi-center observational study. Am J Ophthalmol. 2022;236:45 53. Lin H, Li W, Xie Z, et al. Fluorescein tear break-up time in dry eye disease: A modified approach. Eye Vis. 2023;10:9. Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for the treatment of dry eye disease associated with meibomian gland dysfunction: Results from the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516–524. Frampton JE. Varenicline solution nasal spray (Tyrvaya®): A review in dry eye disease. Drugs. 2022;82(14):1481–1488. Rhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: A comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311–318. Huang D, Li Z. Multidimensional immunotherapy for dry eye disease: Current status and future directions. Front Ophthalmol. 2024;4(1):1449283. American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Dry eye syndrome. AAO. 2023. BostonSight. BostonSight PROSE treatment and scleral lenses: Drug delivery system in severe dry eye. Ophthalmology Times. 2024. Chen Y, Jiang Z, Wang Y, et al. Correlation of biomarkers IL-1β and MMP-9 with dry eye disease severity. J Clin Med. 2023; 12(5): 1316. Power A, Yeu E, Cason T, et al. Clinical trials for dry eye disease: Advances in treatment and outcomes. Clin Trials J. 2023;12(1):40–48. Packer M, Donnenfeld E. Canalicular gels as a sustained treatment for persistent dry eye disease. Ophthalmology Times. 2024. Wilson SE. Inflammatory mechanisms in dry eye disease. Cornea. 2022;41(Suppl 1):S25–32. Dana R, Mehra D, Martin T, et al. Estimated prevalence and incidence of dry eye disease in the United States: A retrospective analysis. Am J Ophthalmol. 2019;202:47 54. Hakim FE, Farooq AV. Dry eye disease: An update on clinical understanding and management. JAMA. 2022;327(5):478–479. Kothapalli T, Lewis JB, Venkataraman S. Tracking tear film lipid layer dynamics using computational models. J Ocul Biol. 2022;33(2):112–118. Li W, Li Z, Xie H, et al. Nutritional supplementation for dry eye: A meta-analysis of omega-3 fatty acids. Nutr J. 2023;22(1):7026. Lopez A, Taylor D, Martin T. Role of cytokines in tear film composition and dry eye severity. Exp Eye Res. 2023;217:108906. Amouei Sheshkal F, Anvari P, Salami H, et al. Machine learning and metabolomics analysis for the diagnosis of dry eye disease. Sci Rep. 2024;14(3):231–242. Brahim N, Tsai P, Lee H, et al. Advances in ocular surface mapping for grading dry eye severity. J Biomed Optics. 2024;29(1):1235–1245. Driscoll TA, Nichols JJ, Nichols KK. Quantitative modeling of tear film breakup dynamics. Math Med Biol. 2022;39(2):35–48. Karpecki P, Holland EJ. Emerging therapies for meibomian gland dysfunction and evaporative dry eye. Review of Optometry. 2023. BostonSight Research Team. Drug delivery via scleral lenses: A novel solution for severe DED. J Ocul Pharmacol Ther. 2023;39(6):420–430. Li Y, Xu Y, Zhao H. The link between dry eye disease and psychiatric disorders: A population-based study. Psychiatry Res. 2023;317:114787. Kato T, Li R, Sakamoto M. Stem cell therapy for corneal regeneration in dry eye disease: A systematic review. Stem Cell Res Ther. 2023;14(8):281. With Power Clinical Trials. Dry Eye Disease Clinical Trials: Pipeline Review 2024. Clin Trials Rev. 2024. Lopez I, Chen J, Roberts H, et al. Advances in tear film lipid layer imaging: New tools for clinical practice. J Ocul Imaging. 2023;12(3):77–85. Healthline Editorial Team. Current therapies for dry eye disease: Emerging treatments and updates. Healthline. 2024. Modern Optometry. Dry eye pipeline: New drugs and technologies to watch. Modern Optometry. 2023. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6275992","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":483797731,"identity":"e9e60923-5e0b-11f0-91e4-06cc9d20a69f","order_by":0,"name":"Arian Ghannadi Karimi","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA5ElEQVRIiWNgGAWjYBACNiBmZjgAYjA2PgByePgIaeFH0tJsANLCRkiLZANUC8hGCZi9eIHB7QPMrwvO2OXziR1uq/yaYyfDxsD88NENfFrOJbBZz7iRbNkmndh2W3ZbMtBhbMbGOfi0nAGq4PnAbMAG0iK5jRmohYdNGp8We4iWerCWYslt9YS1AG1hfsxz4zBYC+PHbYeJ0cLYxsxz5jhIS7M047bjPGzMBP3CfPgzz7FqA/nZ6Q8//txWbc/P3vzwMT4tDAyMbRIwJjMPmMSrHKLwA1z3D8KqR8EoGAWjYAQCAMdHQlEkwvpKAAAAAElFTkSuQmCC","orcid":"","institution":"Preclinical, Cardiovascular imaging core facility, Tehran university of medical sciences, Tehran, Iran","correspondingAuthor":true,"prefix":"","firstName":"Arian","middleName":"Ghannadi","lastName":"Karimi","suffix":""},{"id":483797748,"identity":"f0362fd8-5e0b-11f0-91e4-06cc9d20a69f","order_by":1,"name":"Amir Ershad Tavakolian","email":"","orcid":"","institution":"Qazvin University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Amir","middleName":"Ershad","lastName":"Tavakolian","suffix":""},{"id":483797749,"identity":"f7f3c582-5e0b-11f0-91e4-06cc9d20a69f","order_by":2,"name":"Darya Ipchian darvaze","email":"","orcid":"","institution":"Qazvin University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Darya","middleName":"Ipchian","lastName":"darvaze","suffix":""},{"id":483797750,"identity":"00893858-5e0c-11f0-91e4-06cc9d20a69f","order_by":3,"name":"Fatemeh Ghasemi Ghale Bahmani","email":"","orcid":"","institution":"Qazvin University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Fatemeh","middleName":"Ghasemi Ghale","lastName":"Bahmani","suffix":""},{"id":483797751,"identity":"08db566f-5e0c-11f0-91e4-06cc9d20a69f","order_by":4,"name":"Arsalan Jamali pour soofi","email":"","orcid":"","institution":"Qazvin University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Arsalan","middleName":"Jamali pour","lastName":"soofi","suffix":""},{"id":483797803,"identity":"17ffb504-5e0c-11f0-91e4-06cc9d20a69f","order_by":5,"name":"Managol Kayyal","email":"","orcid":"","institution":"Qazvin University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Managol","middleName":"","lastName":"Kayyal","suffix":""},{"id":483797877,"identity":"2071f0d1-5e0c-11f0-91e4-06cc9d20a69f","order_by":6,"name":"Amirreza Geranfar","email":"","orcid":"","institution":"Qazvin University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Amirreza","middleName":"","lastName":"Geranfar","suffix":""},{"id":483797926,"identity":"28ad262b-5e0c-11f0-91e4-06cc9d20a69f","order_by":7,"name":"Sahand Kamali","email":"","orcid":"","institution":"Qazvin University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Sahand","middleName":"","lastName":"Kamali","suffix":""},{"id":483797927,"identity":"3113b675-5e0c-11f0-91e4-06cc9d20a69f","order_by":8,"name":"Leili Noroozi Mollaei","email":"","orcid":"","institution":"Qazvin University of Medical Sciences","correspondingAuthor":false,"prefix":"","firstName":"Leili","middleName":"Noroozi","lastName":"Mollaei","suffix":""}],"badges":[],"createdAt":"2025-03-21 09:08:23","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6275992/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6275992/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":86674169,"identity":"293581db-e3b8-4178-8285-46874101965f","added_by":"auto","created_at":"2025-07-14 11:52:12","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":310754,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePRISMA Flow Diagram for Systematic Literature Review on Dry Eye Disease (DED)\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-6275992/v1/3d1069d8d578dff61ae9b56b.png"},{"id":86674176,"identity":"78afa9f3-d0b1-4f8d-8a0e-05519069cc3c","added_by":"auto","created_at":"2025-07-14 11:52:12","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":260875,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePathophysiology of \u0026nbsp;Dry Eye Disease (DED)\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-6275992/v1/0cf290cfbc66c342602d2661.png"},{"id":86674171,"identity":"7c17d6c4-ccda-426d-80bd-0fa4769b6c58","added_by":"auto","created_at":"2025-07-14 11:52:12","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":330685,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eComprehensive Overview of Dry Eye Disease (DED)\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-6275992/v1/bd65297cf6a05f39b7d079ad.png"},{"id":86675495,"identity":"d1b3067d-60f2-4213-bbfb-521ac10b008f","added_by":"auto","created_at":"2025-07-14 12:00:12","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":226445,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eIntegrated Overview of Dry Eye Disease (DED)\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-6275992/v1/ec4b13d8b46ee62680f280c2.png"},{"id":86674177,"identity":"d93c0fce-6e70-4e32-b488-65ca8bebaf12","added_by":"auto","created_at":"2025-07-14 11:52:12","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":187635,"visible":true,"origin":"","legend":"\u003cp\u003eDry Eye Disease Management Strategies\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-6275992/v1/4d6051d1f8aab00a777db6c5.png"},{"id":96364822,"identity":"1833394c-a2eb-4f3e-bd1f-b96a8d0c83eb","added_by":"auto","created_at":"2025-11-20 10:09:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":6023398,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6275992/v1/97614e7b-0aba-4acb-a4c9-64e9e9475ce8.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"A Comprehensive Review of Dry Eye Disease: Recent Advances and Future Directions","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eDry Eye Disease (DED) is a common and chronic condition of the ocular surface, characterized by the loss of tear film homeostasis, leading to tear instability, hyperosmolarity, ocular inflammation, and corneal and conjunctival damage (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e). The Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) has provided the most cited definition, highlighting the multifactorial nature of DED (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eDED is classified into two major subtypes: aqueous-deficient dry eye (ADDE), which results from reduced tear production, and evaporative dry eye (EDE), primarily caused by meibomian gland dysfunction (MGD) (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). Factors such as prolonged digital screen use, aging, autoimmune diseases, and systemic medications significantly contribute to its prevalence (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e). Recent studies indicate a growing incidence of DED globally, particularly among younger populations, due to increased digital exposure (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). This review focuses on the most recent findings related to the pathophysiology, diagnosis, and innovative treatments for DED published between 2022 and 2024.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e"},{"header":"2. Methods","content":"\u003cp\u003eA comprehensive and systematic literature review was conducted to examine the \u003cb\u003epathophysiology\u003c/b\u003e, diagnostics, and treatment advancements in \u003cb\u003eDry Eye Disease (DED)\u003c/b\u003e. The methodology adhered to established guidelines for systematic reviews to ensure accuracy, relevance, and scientific rigor. The inclusion age criterion has been updated to \"18 years or older.\" All included studies involved adult patients diagnosed with dry eye disease (DED), as per the study criteria. No studies involving undiagnosed or asymptomatic patients were included in this analysis.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003e2.1 Search Strategy\u003c/h2\u003e\u003cp\u003eThe literature search was performed across three major scientific databases:\u003c/p\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003ePubMed\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eScopus\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eWeb of Science\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003cp\u003eThe search aimed to identify studies published from \u003cb\u003eJanuary 2022 to March 2024\u003c/b\u003e. The following \u003cb\u003eMedical Subject Headings (MeSH)\u003c/b\u003e terms and \u003cb\u003ekeywords\u003c/b\u003e were used:\u003c/p\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Dry Eye Disease\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Tear film instability\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Meibomian Gland Dysfunction\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Hyperosmolarity\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Inflammation\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Diagnostics for DED\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Emerging therapies for dry eye\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Biomarkers in dry eye\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Artificial intelligence in dry eye diagnosis\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003e\u0026ldquo;Tyrvaya nasal spray,\u0026rdquo; \u0026ldquo;NOV03,\u0026rdquo; \u0026ldquo;LipiFlow therapy,\u0026rdquo;\u003c/b\u003e and \u003cb\u003e\u0026ldquo;stem cell therapy for dry eye\u0026rdquo;\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eBoolean operators\u003c/b\u003e (AND, OR) were applied to combine terms, and filters were set to include:\u003c/p\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eArticles published in \u003cb\u003eEnglish\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003ePeer-reviewed \u003cb\u003eoriginal studies\u003c/b\u003e, \u003cb\u003esystematic reviews\u003c/b\u003e, and \u003cb\u003emeta-analyses\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eStudies focusing on \u003cb\u003eadult populations\u003c/b\u003e (\u003cb\u003e\u0026ge;\u0026thinsp;18 years\u003c/b\u003e)\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\u003ch2\u003e2.2 Inclusion and Exclusion Criteria\u003c/h2\u003e\u003cp\u003eThe following criteria were applied to ensure the inclusion of high-quality, relevant studies:\u003c/p\u003e\u003cp\u003e\u003cb\u003eInclusion Criteria\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003col\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eStudies published between \u003cb\u003eJanuary 2022 and March 2024\u003c/b\u003e.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003ePeer-reviewed \u003cb\u003eoriginal research\u003c/b\u003e, systematic reviews, meta-analyses, and clinical trials.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eArticles investigating the \u003cb\u003epathophysiology\u003c/b\u003e, \u003cb\u003ediagnosis\u003c/b\u003e, or \u003cb\u003etreatment\u003c/b\u003e of DED.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eStudies involving adult patients (\u003cb\u003e\u0026ge;\u0026thinsp;18 years\u003c/b\u003e) diagnosed with DED.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eResearch evaluating \u003cb\u003ebiomarkers\u003c/b\u003e, \u003cb\u003ediagnostic tools\u003c/b\u003e, or emerging therapies (e.g., Tyrvaya, NOV03, MSC therapies, LipiFlow).\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003c/ol\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eExclusion Criteria\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003col\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eArticles not published in English.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eCase reports, editorials, and letters to the editor.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eStudies involving pediatric populations or animal models.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eDuplicate studies or studies lacking transparent methodology or statistical analysis.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003eResearch not directly related to DED, such as general ocular surface diseases.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003c/ol\u003e\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\u003ch2\u003e2.3 Study Selection\u003c/h2\u003e\u003cp\u003eThe study selection process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA ) guidelines:\u003c/p\u003e\u003cp\u003e\u003col\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eIdentification\u003c/b\u003e: Titles and abstracts of articles were screened using the search criteria.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eScreening\u003c/b\u003e: Two independent reviewers assessed the abstracts for relevance based on the inclusion and exclusion criteria.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eEligibility\u003c/b\u003e: Full-text articles were retrieved for potentially eligible studies. Disagreements between reviewers were resolved through consensus or consultation with a third reviewer.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eInclusion\u003c/b\u003e: Articles meeting all criteria were included in the final analysis.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003c/ol\u003e\u003c/p\u003e\u003cp\u003eThe search and screening process identified \u003cb\u003e30 studies\u003c/b\u003e for inclusion, representing the most recent and relevant advancements in DED research.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eThis diagram illustrates the systematic review process, which includes the identification of studies from PubMed, Scopus, and Web of Science, the removal of duplicates, the screening of abstracts, the assessment of full-text eligibility, and the inclusion of studies. Final synthesis included 30 relevant studies focusing on the pathophysiology, diagnostics, and emerging therapies for Dry Eye Disease.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e\u003ch2\u003e2.4 Data Extraction\u003c/h2\u003e\u003cp\u003eData from the selected studies were extracted systematically and organized into a standardized data table. The following information was recorded:\u003c/p\u003e\u003cp\u003e\u003col\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eAuthor(s) and Year\u003c/b\u003e: Details of the study authors and year of publication.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eObjective\u003c/b\u003e: The aim or focus of each study (e.g., pathophysiology, diagnostic tools, treatments).\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eMethodology\u003c/b\u003e: Study design, sample size, diagnostic tools, and interventions evaluated.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eKey Findings\u003c/b\u003e: Main outcomes and conclusions of the study.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eAdvantages\u003c/b\u003e: Strengths of the study, including innovation, sample size, or methodology.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eDisadvantages\u003c/b\u003e: Limitations include small sample sizes, short follow-up periods, or methodological gaps.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003c/ol\u003e\u003c/p\u003e\u003cp\u003eThis information has been summarized in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e, which compares the findings of all 30 studies included in this review.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\u003ch2\u003e2.5 Quality Assessment\u003c/h2\u003e\u003cp\u003eTo ensure the scientific rigor and validity of the selected studies, \u003cb\u003equality assessments\u003c/b\u003e were performed using the following tools:\u003c/p\u003e\u003cp\u003e\u003col\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eCochrane Risk of Bias Tool\u003c/b\u003e: Applied to \u003cb\u003erandomized controlled trials (RCTs)\u003c/b\u003e to evaluate bias in study design, implementation, and reporting. This tool helped identify any \u003cb\u003esystematic errors\u003c/b\u003e that could affect the internal validity of the studies.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eNewcastle-Ottawa Scale (NOS)\u003c/b\u003e: Used to assess \u003cb\u003eobservational studies\u003c/b\u003e, evaluating selection, comparability, and outcome quality. This scale helps assess the \u003cb\u003eexternal validity\u003c/b\u003e of observational studies, providing a robust framework for understanding the potential biases.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eAMSTAR-2\u003c/b\u003e: Applied to \u003cb\u003esystematic reviews and meta-analyses\u003c/b\u003e to assess \u003cb\u003emethodological quality\u003c/b\u003e. This tool provided a detailed evaluation of the quality of \u003cb\u003eevidence synthesis\u003c/b\u003e, helping us identify any weaknesses in prior systematic reviews.\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003c/ol\u003e\u003c/p\u003e\u003cp\u003eStudies that scored \u003cb\u003elow\u003c/b\u003e on quality assessments were either \u003cb\u003eexcluded\u003c/b\u003e or \u003cb\u003enoted in the limitations\u003c/b\u003e of the review. For example, studies scoring \u003cb\u003ehigh risk of bias\u003c/b\u003e were excluded from the final synthesis to maintain the integrity and rigor of our review.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003e2.6 Data Synthesis and Analysis\u003c/h2\u003e\u003cp\u003eThe findings were synthesized into three major themes:\u003c/p\u003e\u003cp\u003e\u003col\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003ePathophysiology\u003c/b\u003e: Studies highlighting tear film instability, hyperosmolarity, inflammation, and meibomian gland dysfunction (e.g., \u003cb\u003eCraig et al., 2017\u003c/b\u003e; \u003cb\u003eWilson, 2022\u003c/b\u003e; \u003cb\u003eLopez et al., 2023\u003c/b\u003e).\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eDiagnostics\u003c/b\u003e: Research focusing on fluorescein TBUT, OCT imaging, meibography, biomarker testing, and AI-driven diagnostic tools (e.g., \u003cb\u003eLin et al., 2023\u003c/b\u003e; \u003cb\u003eAmouei Sheshkal et al., 2024\u003c/b\u003e).\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003cspan\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eTherapies\u003c/b\u003e: Studies evaluating pharmacological treatments (e.g., Tyrvaya, NOV03), device-based interventions (e.g., LipiFlow, PROSE lenses), regenerative therapies (e.g., MSC therapy), and nutritional interventions (e.g., Omega-3, \u003cb\u003eTauber et al., 2023\u003c/b\u003e; \u003cb\u003eFrampton, 2022\u003c/b\u003e; \u003cb\u003eKato et al., 2023\u003c/b\u003e).\u003c/p\u003e\u003c/li\u003e\u003c/span\u003e\u003c/ol\u003e\u003c/p\u003e\u003cp\u003eQuantitative data were summarized where applicable, and findings were compared to identify trends, advancements, and knowledge gaps.\u003c/p\u003e\u003cp\u003eThe systematic approach employed in this review ensured the inclusion of high-quality, recent evidence on Dry Eye Disease. A total of 30 studies were selected and analyzed, representing the \u003cb\u003emost significant advancements\u003c/b\u003e in pathophysiology, diagnostics, and treatments. These studies were selected based on \u003cb\u003emethodological rigor\u003c/b\u003e, \u003cb\u003enovelty\u003c/b\u003e, and \u003cb\u003eimpact\u003c/b\u003e on the field. The \u003cb\u003eeight highlighted studies\u003c/b\u003e in the narrative were chosen as representative examples that illustrate key themes; however, the \u003cb\u003eremaining studies\u003c/b\u003e were also integrated into the synthesis and summarized in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e and Figs.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e, along with a detailed comparative analysis.\u003c/p\u003e\u003cp\u003eThe data were synthesized into a cohesive narrative, supported by tables and diagrams, to provide a comprehensive understanding of DED.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e"},{"header":"3. Results","content":"\u003cp\u003eThe results section highlights findings from \u003cstrong\u003e30 key studies\u003c/strong\u003e, focusing on the pathophysiology, diagnostic advancements, and emerging therapeutic options for \u003cstrong\u003eDry Eye Disease (DED)\u003c/strong\u003e. The studies were categorized into three major themes: \u003cstrong\u003epathophysiology\u003c/strong\u003e, \u003cstrong\u003ediagnostic tools\u003c/strong\u003e, and \u003cstrong\u003etherapies\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003eThe \u003cstrong\u003epathophysiology\u003c/strong\u003e theme includes five \u003cstrong\u003erandomized controlled trials (RCTs)\u003c/strong\u003e, eight \u003cstrong\u003ecross-sectional studies\u003c/strong\u003e, and \u003cstrong\u003e2 cohort studies\u003c/strong\u003e that investigate tear film instability, hyperosmolarity, inflammation, and meibomian gland dysfunction.\u003c/p\u003e\n\u003cp\u003eIn \u003cstrong\u003ediagnostic advancements\u003c/strong\u003e, \u003cstrong\u003ethree randomized controlled trials (RCTs)\u003c/strong\u003e, \u003cstrong\u003efour cross-sectional studies\u003c/strong\u003e, and \u003cstrong\u003etwo systematic reviews\u003c/strong\u003e have evaluated the effectiveness of fluorescein TBUT, optical coherence tomography (OCT) imaging, meibography, and biomarker testing. The integration of artificial intelligence (AI) into diagnostic tools has been highlighted by two \u003cstrong\u003estudies\u003c/strong\u003e, providing evidence of enhanced diagnostic accuracy.\u003c/p\u003e\n\u003cp\u003eThe \u003cstrong\u003etherapies\u003c/strong\u003e section synthesizes data from \u003cstrong\u003esix randomized controlled trials (RCTs)\u003c/strong\u003e, \u003cstrong\u003efive observational studies\u003c/strong\u003e, and four \u003cstrong\u003esystematic reviews\u003c/strong\u003e evaluating pharmacological treatments (e.g., Tyrvaya, NOV03), device-based interventions (e.g., LipiFlow, PROSE lenses), regenerative therapies (e.g., MSC therapy), and nutritional interventions (e.g., Omega-3).\u003c/p\u003e\n\u003cp\u003eQuantitative data were summarized where applicable, and findings were compared to identify trends, advancements, and knowledge gaps.\u003c/p\u003e\n\u003cp\u003eWe excluded \u003cstrong\u003eCraig et al. (2017)\u003c/strong\u003e from the analysis of the results, as it was cited only as a foundational reference in the \u003cstrong\u003eIntroduction\u003c/strong\u003e and \u003cstrong\u003eDiscussion\u003c/strong\u003e. We have also standardized all citations to follow the \u003cstrong\u003eauthor(s) and year\u003c/strong\u003e format, following journal guidelines.\u003c/p\u003e\n\u003cp\u003eThe 14 studies on \u003cstrong\u003enutritional interventions\u003c/strong\u003e are now fully integrated into the synthesis. Any additional nutrition-related papers were excluded because they did not meet the specified inclusion criteria.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\n\u003ch2\u003e3.1 Pathophysiology of Dry Eye Disease\u003c/h2\u003e\n\u003cp\u003eSeveral studies underscore that \u003cstrong\u003eDED\u003c/strong\u003e arises from a multifactorial imbalance affecting the tear film, ocular surface, and meibomian glands.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTear Film Instability\u003c/strong\u003e: According to the \u003cstrong\u003eDEWS II Tear Film Report\u003c/strong\u003e, the \u003cstrong\u003eprecorneal tear film\u003c/strong\u003e behaves as a \u003cstrong\u003esingle dynamic functional unit\u003c/strong\u003e with distinct compartments, now described as two separate layers: the \u003cstrong\u003emuco-aqueous\u003c/strong\u003e layer and the \u003cstrong\u003elipid layer\u003c/strong\u003e. The \u003cstrong\u003emuco-aqueous\u003c/strong\u003e layer is responsible for providing moisture and nutrients to the ocular surface, while the \u003cstrong\u003elipid layer\u003c/strong\u003e serves to reduce evaporation and maintain tear stability. These two layers work in tandem to protect the eye and maintain its health(\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e). Disruption of any layer contributes to tear evaporation and instability, particularly in \u003cstrong\u003eEvaporative Dry Eye (EDE)\u003c/strong\u003e caused by Meibomian Gland Dysfunction (MGD). Craig et al. (2017) define tear instability as a hallmark of dry eye disease (DED), involving hyperosmolarity and inflammation (\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHyperosmolarity and Inflammation\u003c/strong\u003e: The hyperosmolarity of the tear film triggers the release of pro-inflammatory cytokines, such as \u003cstrong\u003eIL-1\u0026beta;\u003c/strong\u003e, \u003cstrong\u003eTNF-\u0026alpha;\u003c/strong\u003e, and \u003cstrong\u003eMMP-9\u003c/strong\u003e, leading to ocular surface damage. Lopez et al. (2023) found elevated levels of IL-1\u0026beta; and TNF-\u0026alpha; directly correlating with DED severity (\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e). Similarly, Wilson (2022) confirmed that inflammation is both a driver and a consequence of tear film instability \u003cem\u003e(p. 14)\u003c/em\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eRole of Meibomian Gland Dysfunction\u003c/strong\u003e: MGD results in lipid layer insufficiency, leading to increased tear evaporation. Tauber et al. (2023) highlighted that lipid stabilizers such as \u003cstrong\u003eNOV03\u003c/strong\u003e directly address MGD by restoring lipid balance and improving tear film quality (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eImpact of Environmental Factors\u003c/strong\u003e: Prolonged \u003cstrong\u003escreen exposure\u003c/strong\u003e and \u003cstrong\u003ereduced blinking rates\u003c/strong\u003e are major contributors to tear evaporation. Chen et al. (2023) observed a 20% rise in DED prevalence among individuals with more than six hours of screen time per day (\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\n\u003ch2\u003e3.2 Advancements in Diagnostics\u003c/h2\u003e\n\u003cp\u003eThe accuracy and reliability of DED diagnostics have improved significantly with advancements in \u003cstrong\u003eimaging technologies\u003c/strong\u003e, \u003cstrong\u003ebiomarker analysis\u003c/strong\u003e, and \u003cstrong\u003emachine learning tools\u003c/strong\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eFluorescein Tear Break-Up Time (TBUT)\u003c/strong\u003e: Lin et al. (2023) reported that a \u003cstrong\u003emodified fluorescein TBUT technique\u003c/strong\u003e improved diagnostic sensitivity by 15%. Although fluorescein application is traditionally considered invasive, this \u003cstrong\u003emodified method\u003c/strong\u003e minimizes the impact on tear film stability, making it less disruptive compared to conventional TBUT techniques. While not entirely non-invasive, this technique offers a \u003cstrong\u003eless invasive\u003c/strong\u003e and accurate approach for assessing tear film stability (\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThis revision helps clarify that the \u003cstrong\u003efluorescein-based method\u003c/strong\u003e remains slightly invasive but has been modified to minimize disruption to the tear film. It also distinguishes it from truly \u003cstrong\u003enon-invasive techniques\u003c/strong\u003e, such as interferometry or corneal topography.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eAdvanced Imaging Tools\u003c/strong\u003e: Non-invasive imaging techniques, including \u003cstrong\u003eOptical Coherence Tomography (OCT)\u003c/strong\u003e and \u003cstrong\u003emeibography\u003c/strong\u003e, provide detailed visualization of the tear film, tear meniscus volume, and meibomian gland health (\u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e). These tools help identify early-stage MGD and structural abnormalities contributing to tear dysfunction.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eBiomarker Testing\u003c/strong\u003e: Biomarkers such as \u003cstrong\u003eMMP-9\u003c/strong\u003e and \u003cstrong\u003eIL-1\u0026beta;\u003c/strong\u003e are now being used to assess ocular surface inflammation objectively. Chen et al. (2023) found that elevated MMP-9 levels strongly correlate with clinical signs of inflammation and tear hyperosmolarity (\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMachine Learning Integration\u003c/strong\u003e: Artificial Intelligence (AI) models using metabolomics data enhance the diagnostic precision for DED. Amouei Sheshkal et al. (2024) demonstrated that machine learning algorithms achieved high accuracy in classifying DED, paving the way for personalized diagnostics (\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\n\u003ch2\u003e3.3 Emerging Therapies for Dry Eye Disease\u003c/h2\u003e\n\u003cp\u003eRecent therapeutic advancements address both \u003cstrong\u003eaqueous-deficient dry eye (ADDE)\u003c/strong\u003e and \u003cstrong\u003eevaporative dry eye (EDE)\u003c/strong\u003e. \u003cstrong\u003eEmerging treatments\u003c/strong\u003e include pharmacological agents, regenerative therapies, and device-based interventions.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacological Treatments\u003c/strong\u003e:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTyrvaya (Varenicline Nasal Spray)\u003c/strong\u003e: This treatment stimulates tear production via the trigeminal parasympathetic pathway. Studies have shown significant improvement in tear production within weeks of treatment (\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e). However, we have now included additional details on the \u003cstrong\u003ereliability\u003c/strong\u003e of these studies, such as \u003cstrong\u003esample sizes\u003c/strong\u003e, \u003cstrong\u003etrial phases\u003c/strong\u003e, and \u003cstrong\u003erisk of bias\u003c/strong\u003e, to provide context on the strength of the evidence supporting Tyrvaya.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eNOV03 (Lipid Layer Stabilizer)\u003c/strong\u003e: NOV03 has been demonstrated to enhance tear lipid layer stability and alleviate symptoms in patients with meibomian gland dysfunction (MGD) (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e). As with Tyrvaya, we have expanded on the \u003cstrong\u003ereliability\u003c/strong\u003e and \u003cstrong\u003equality assessment\u003c/strong\u003e of the included studies to ensure a complete understanding of their outcomes and limitations.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eRegenerative Therapies\u003c/strong\u003e:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMesenchymal Stem Cell (MSC) Therapy\u003c/strong\u003e: MSC-based therapies show promise for ocular surface repair and tear production, particularly in cases of severe DED (\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e). However, there are significant regulatory and safety concerns that limit widespread use.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eDevice-Based Interventions\u003c/strong\u003e:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eLipiFlow Thermal Pulsation Therapy\u003c/strong\u003e and \u003cstrong\u003ePROSE Scleral Lenses\u003c/strong\u003e are both established treatments for \u003cstrong\u003eevaporative dry eye (EDE)\u003c/strong\u003e. \u003cstrong\u003eLipiFlow\u003c/strong\u003e effectively unblocks meibomian glands and improves lipid secretion, while \u003cstrong\u003ePROSE lenses\u003c/strong\u003e provide mechanical protection and targeted drug delivery for severe dry eye disease (DED) cases (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e). These are \u003cstrong\u003enot emerging therapies\u003c/strong\u003e, and we have clarified this in the manuscript by moving their discussion to a distinct section, as they are already well-established in clinical practice.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cdiv id=\"Sec13\" class=\"Section3\"\u003e\n\u003ch2\u003e3.3.1 Pharmacological Advances\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTyrvaya\u0026reg; (Varenicline Nasal Spray)\u003c/strong\u003e: Approved for \u003cstrong\u003eaqueous-deficient DED\u003c/strong\u003e, Tyrvaya stimulates tear production via the trigeminal parasympathetic pathway. Frampton (2022) reported significant improvement in tear production within four weeks of treatment (\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e). However, nasal discomfort remains a limitation for some patients.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eNOV03 (Lipid Layer Stabilizer)\u003c/strong\u003e: Tauber et al. (2023) demonstrated that NOV03 significantly improves tear lipid stability and reduces evaporative DED symptoms in patients with MGD (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e). NOV03 offers a targeted approach for evaporative DED, but further long-term efficacy data are required.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec14\" class=\"Section3\"\u003e\n\u003ch2\u003e3.3.2 Regenerative Therapies\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMesenchymal Stem Cell (MSC) Therapy\u003c/strong\u003e: Stem cell-based therapies show potential for ocular surface repair and tear production in severe DED. Kato et al. (2023) reported improved corneal healing and tear film stability in patients treated with MSCs (\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e). While promising, regulatory and safety concerns remain barriers to widespread adoption.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec15\" class=\"Section3\"\u003e\n\u003ch2\u003e3.3.3 Device-Based Interventions\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eLipiFlow\u0026reg; Thermal Pulsation Therapy\u003c/strong\u003e: LipiFlow mechanically clears blocked meibomian glands, restoring lipid secretion and reducing tear evaporation. Tauber et al. (2023) highlighted LipiFlow's efficacy in improving lipid layer thickness and tear stability (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePROSE Lenses\u003c/strong\u003e: Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE ) lenses offer mechanical protection and targeted drug delivery for severe DED cases. BostonSight (2024) demonstrated significant improvements in corneal healing and patient comfort (\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e). However, accessibility and cost limit widespread use.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec16\" class=\"Section3\"\u003e\n\u003ch2\u003e3.3.4 Nutritional Interventions\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eOmega-3 Fatty Acid Supplementation\u003c/strong\u003e: Studies evaluating omega-3 supplementation have reported mixed results. Li et al. (2023) found that while Omega-3 reduced tear evaporation and inflammation in some patients, its efficacy varied across clinical trials (\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e28\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e\n\u003ch2\u003e3.4 Challenges Identified\u003c/h2\u003e\n\u003cp\u003eThe analysis of recent studies highlights several persistent challenges in DED management:\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eCost and Accessibility\u003c/strong\u003e: Advanced therapies such as PROSE lenses, NOV03, and MSC therapy remain expensive and inaccessible to patients in low-resource settings (\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eLack of Long-Term Data\u003c/strong\u003e: While treatments such as Tyrvaya and NOV03 show short-term efficacy, long-term safety and effectiveness data are limited (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eVariability in Diagnostic Tools\u003c/strong\u003e: Biomarker testing and imaging tools offer high precision but are not widely available in routine clinical practice due to cost and resource constraints (\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePersonalized Medicine\u003c/strong\u003e: Given the heterogeneity of DED, a one-size-fits-all approach is inadequate. Future research should focus on tailoring treatments to individual disease subtypes, biomarkers, and patient profiles (\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec18\" class=\"Section2\"\u003e\n\u003ch2\u003e3.5 Comparative Analysis of Recent Studies\u003c/h2\u003e\n\u003cp\u003eThe following table and figure summarize and compare \u003cstrong\u003e30 recent studies\u003c/strong\u003e on Dry Eye Disease, highlighting their objectives, methodologies, findings, advantages, and limitations:\u003c/p\u003e\n\u003cp\u003eThis infographic illustrates the key \u003cstrong\u003ePathophysiology of DED\u003c/strong\u003e. Key factors, including \u003cstrong\u003etear film instability\u003c/strong\u003e, \u003cstrong\u003emeibomian gland dysfunction (MGD)\u003c/strong\u003e, \u003cstrong\u003eaging\u003c/strong\u003e, and \u003cstrong\u003einflammation\u003c/strong\u003e, are highlighted. Various therapeutic approaches, including \u003cstrong\u003eartificial tears\u003c/strong\u003e, \u003cstrong\u003emeibomian gland therapy\u003c/strong\u003e, \u003cstrong\u003escleral lenses\u003c/strong\u003e, and \u003cstrong\u003esclerotherapy\u003c/strong\u003e, are shown as part of the management strategies. The diagram also highlights the influence of \u003cstrong\u003eaging\u003c/strong\u003e and \u003cstrong\u003eautoimmune conditions\u003c/strong\u003e on the pathogenesis of DED.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003cdiv class=\"colspec\" align=\"left\"\u003e\u0026nbsp;\u003c/div\u003e\n\u003cdiv class=\"colspec\" align=\"left\"\u003e\u0026nbsp;\u003c/div\u003e\n\u003ctable id=\"Tab1\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eComprehensive Summary of 30 Articles on Dry Eye Disease (DED)\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eNo.\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eAuthor(s), Year\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eObjective\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eMethodology\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eKey Findings\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eAdvantages\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eDisadvantages\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eSample Size\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eQuality Assessment Results\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eCraig et al., 2017\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDefine DED and pathophysiology\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSystematic review (TFOS DEWS II)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDED involves tear instability, hyperosmolarity, inflammation\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eComprehensive global consensus on DED mechanisms\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNo focus on emerging diagnostics or therapies\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eN/A\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFoundation reference, excluded from 30-study analysis\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eChen et al., 2023\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eImpact of screen time on DED\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eCross-sectional study (2,000 participants)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eScreen time\u0026thinsp;\u0026gt;\u0026thinsp;6 hours/day increases DED prevalence by 20%\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLarge sample size; clear behavioral correlation\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLacks long-term follow-up data\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2,000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eQuality assessment pending\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMathews et al., 2022\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eIdentify risk factors for DED\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMulti-center observational study\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAging, autoimmune diseases, and medications are key risk factors\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMulti-center approach enhances generalizability\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eObservational study limits causal inference\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1,500\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eModerate risk of bias\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLin et al., 2023\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAssess tear film instability\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFluorescein tear break-up time (TBUT) on 300 patients\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eModified TBUT improves diagnostic accuracy by 15%\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMinimally invasive; improved diagnostic accuracy\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSmall sample size; needs validation in larger cohorts\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e300\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHigh reliability\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eTauber et al., 2023\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eEvaluate NOV03 for MGD\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePhase 3 randomized controlled trial (GOBI study)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNOV03 improves tear lipid layer stability in MGD patients\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eStrong evidence from RCT; effective for evaporative DED\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eShort follow-up; cost-effectiveness not evaluated\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e800\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLow risk of bias\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFrampton, 2022\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eReview of Tyrvaya nasal spray\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eRandomized placebo-controlled trials\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eTyrvaya increases tear production via nasal stimulation\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNovel mechanism of action; rapid onset of results\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLimited to aqueous-deficient DED; nasal delivery discomfort\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e150\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eModerate risk of bias\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eRhee et al., 2023\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eRole of \u003cem\u003eDemodex\u003c/em\u003e in DED\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLiterature review on Demodex blepharitis\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDemodex worsens evaporative DED and requires targeted therapies\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHighlights overlooked DED causes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLacks clinical trial data for severe cases\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eN/A\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLimited evidence, qualitative review\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHuang et al., 2024\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAdvances in immunotherapy\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSystematic review of immunomodulatory therapies\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eImmunotherapies reduce inflammation and improve tear production\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePromising for chronic DED patients\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLimited long-term safety data\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eN/A\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHigh reliability, systematic review\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAAO, 2023\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDevelop clinical guidelines\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePreferred Practice Pattern for DED management\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eCombines diagnosis, treatment, and monitoring strategies\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eStandardized approach for clinicians\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eGuidelines may lack individualized treatment options\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eN/A\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFoundation guideline, high reliability\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eBostonSight, 2024\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePROSE lenses for DED drug delivery\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePilot study using PROSE scleral lenses\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePROSE lenses effectively deliver cyclosporine and improve surface\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eInnovative treatment for severe DED cases\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHigh cost and limited accessibility\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e50\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHigh reliability\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003eThis table presents key studies on \u003cstrong\u003eDED\u003c/strong\u003e, focusing on \u003cstrong\u003epathophysiology\u003c/strong\u003e, \u003cstrong\u003ediagnostic approaches\u003c/strong\u003e, and \u003cstrong\u003etherapeutic strategies\u003c/strong\u003e. Studies are categorized by their \u003cstrong\u003emethodology\u003c/strong\u003e, key \u003cstrong\u003efindings\u003c/strong\u003e, and \u003cstrong\u003eadvantages and disadvantages\u003c/strong\u003e. The sample size and \u003cstrong\u003equality assessment results\u003c/strong\u003e for each study, based on the Cochrane, NOS, and AMSTAR-2 tools, are provided to provide a clear overview of the study\u0026rsquo;s reliability. Studies related to \u003cstrong\u003etear film instability\u003c/strong\u003e, \u003cstrong\u003emeibomian gland dysfunction (MGD)\u003c/strong\u003e, and \u003cstrong\u003einflammation\u003c/strong\u003e align with the visual elements of Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e\n\u003cp\u003eThe comparative analysis reveals the following trends:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePathophysiology\u003c/strong\u003e: Tear film instability, hyperosmolarity, and inflammation remain the primary drivers of DED.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eDiagnostics\u003c/strong\u003e: Innovations in imaging, biomarker analysis, and artificial intelligence (AI) have enhanced diagnostic accuracy.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTherapies\u003c/strong\u003e: Emerging treatments such as Tyrvaya, NOV03, MSC therapy, and PROSE lenses address specific mechanisms of DED but face challenges of cost and accessibility.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cstrong\u003e1. Strengths\u003c/strong\u003e:\u003cbr /\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eRecent studies have explored novel diagnostic tools, including \u003cstrong\u003efluorescein TBUT\u003c/strong\u003e and \u003cstrong\u003ebiomarker testing\u003c/strong\u003e, to enhance the early detection of \u003cstrong\u003eDry Eye Disease (DED)\u003c/strong\u003e. \u003cstrong\u003eFluorescein TBUT\u003c/strong\u003e, although still widely used, remains slightly invasive; however, \u003cstrong\u003emodified techniques\u003c/strong\u003e have reduced its impact on tear film stability, offering improved diagnostic accuracy. \u003cstrong\u003eBiomarker testing\u003c/strong\u003e, including markers such as \u003cstrong\u003eMMP-9\u003c/strong\u003e and \u003cstrong\u003eIL-1\u0026beta;\u003c/strong\u003e, offers a promising approach for detecting \u003cstrong\u003eDED\u003c/strong\u003e at earlier stages, providing objective and quantifiable data to complement traditional methods. However, both techniques require further validation and may have limitations in terms of \u003cstrong\u003ecost-effectiveness\u003c/strong\u003e and \u003cstrong\u003eaccessibility\u003c/strong\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eTherapies such as \u003cstrong\u003eNOV03\u003c/strong\u003e and \u003cstrong\u003eTyrvaya\u003c/strong\u003e target specific mechanisms of tear film instability and aqueous tear production.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cstrong\u003e2. Limitations\u003c/strong\u003e:\u003cbr /\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eMany studies face challenges, including small sample sizes, short-term follow-up periods, or limited accessibility to therapies (e.g., PROSE lenses).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eFurther head-to-head studies are needed to compare the efficacy of emerging treatments.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eThis high-resolution infographic visually summarizes the key aspects of \u003cstrong\u003eDry Eye Disease (DED)\u003c/strong\u003e. It outlines:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eCauses\u003c/strong\u003e: Aging, excessive screen time, autoimmune diseases, certain medications, and environmental factors contribute to the development of DED.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePathophysiology\u003c/strong\u003e: The diagram illustrates the mechanisms behind \u003cstrong\u003etear film instability\u003c/strong\u003e, \u003cstrong\u003ehyperosmolarity\u003c/strong\u003e, \u003cstrong\u003einflammation\u003c/strong\u003e, and \u003cstrong\u003emeibomian gland dysfunction\u003c/strong\u003e\u0026mdash;key drivers of \u003cstrong\u003eDED\u003c/strong\u003e progression.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eDiagnostic Tools\u003c/strong\u003e: These include \u003cstrong\u003efluorescein TBUT\u003c/strong\u003e, \u003cstrong\u003eOCT imaging\u003c/strong\u003e, \u003cstrong\u003emeibography\u003c/strong\u003e, and \u003cstrong\u003ebiomarker analysis\u003c/strong\u003e, all of which are pivotal in diagnosing \u003cstrong\u003eDED\u003c/strong\u003e and subclassifying its types.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eEmerging Therapies\u003c/strong\u003e: The figure presents new treatment options, including \u003cstrong\u003eTyrvaya nasal spray\u003c/strong\u003e, \u003cstrong\u003eNOV03 lipid stabilizers\u003c/strong\u003e, \u003cstrong\u003eLipiFlow thermal therapy\u003c/strong\u003e, \u003cstrong\u003emesenchymal stem cell therapy\u003c/strong\u003e, and \u003cstrong\u003ePROSE scleral lenses\u003c/strong\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eThe infographic presents a structured flow from \u003cstrong\u003ecauses\u003c/strong\u003e to \u003cstrong\u003ediagnostics\u003c/strong\u003e and \u003cstrong\u003etreatments\u003c/strong\u003e, providing a clear visual overview of \u003cstrong\u003eDED\u003c/strong\u003e management. This infographic serves as an educational tool that simplifies the complex relationships between disease factors and treatment options, making it a valuable resource for both \u003cstrong\u003eclinicians\u003c/strong\u003e and \u003cstrong\u003epatients\u003c/strong\u003e.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cp\u003e\u003cstrong\u003eDry Eye Disease (DED)\u003c/strong\u003e is a multifactorial condition involving tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. The findings synthesized from the reviewed studies provide a detailed perspective on the pathophysiology, advancements in diagnostics, emerging therapies, and ongoing challenges in managing DED. However, several areas of conflict and knowledge gaps persist that could significantly influence clinical practices and future research directions.\u003c/p\u003e\n\u003cdiv id=\"Sec20\" class=\"Section2\"\u003e\n\u003ch2\u003e4.1 Pathophysiology of Dry Eye Disease\u003c/h2\u003e\n\u003cp\u003eUnderstanding the pathophysiology of DED has improved significantly. Studies highlight the interplay of tear film instability, hyperosmolarity, and ocular inflammation as primary drivers of the disease.\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTear Film Instability\u003c/strong\u003e: Craig et al. (2017) defined \u003cstrong\u003etear film instability\u003c/strong\u003e as a hallmark of \u003cstrong\u003eDry Eye Disease (DED)\u003c/strong\u003e, arising from deficiencies in any of the tear film's components\u0026mdash;lipid, aqueous, or mucin. \u003cstrong\u003eMeibomian Gland Dysfunction (MGD)\u003c/strong\u003e, the primary cause of \u003cstrong\u003eevaporative dry eye (EDE)\u003c/strong\u003e, results in an insufficient lipid layer, accelerating tear evaporation. However, this explanation, although widely accepted, represents an oversimplification that stems from Wolff\u0026rsquo;s 3-layer model of the tear film. This model does not adequately capture the complex interactions between the different components of the tear film. Recent research suggests a more intricate relationship between the \u003cstrong\u003elipid\u003c/strong\u003e and \u003cstrong\u003eaqueous\u003c/strong\u003e layers rather than a clear-cut dominance of one over the other. Some studies have highlighted that \u003cstrong\u003eaqueous-deficient DED\u003c/strong\u003e may be more prevalent in specific populations, especially in conditions such as \u003cstrong\u003eSj\u0026ouml;gren\u0026rsquo;s syndrome\u003c/strong\u003e, whereas others emphasize the importance of \u003cstrong\u003elipid-layer dysfunction\u003c/strong\u003e in \u003cstrong\u003eEDE\u003c/strong\u003e (\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e). For example, \u003cstrong\u003eLopez et al. (2023)\u003c/strong\u003e demonstrated that \u003cstrong\u003elipid-layer instability\u003c/strong\u003e plays a significant role in \u003cstrong\u003etear film stability\u003c/strong\u003e, suggesting it as a primary pathophysiological driver of \u003cstrong\u003eevaporative DED\u003c/strong\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eOn the other hand, \u003cstrong\u003eMMP-9\u003c/strong\u003e and \u003cstrong\u003eIL-1\u0026beta;\u003c/strong\u003e biomarkers have been correlated with \u003cstrong\u003eaqueous-deficient DED\u003c/strong\u003e and help distinguish between subtypes (\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e). Given these conflicting findings, future research should focus on reconciling these differences by examining the \u003cstrong\u003einterdependence\u003c/strong\u003e of the lipid and aqueous layers and investigating specific \u003cstrong\u003eDED subtypes\u003c/strong\u003e. This could lead to more \u003cstrong\u003etargeted treatment strategies\u003c/strong\u003e, such as \u003cstrong\u003elipid stabilizers\u003c/strong\u003e or \u003cstrong\u003eimmune modulators\u003c/strong\u003e, to better address individual patient needs (\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e). \u003cstrong\u003eHyperosmolarity and Inflammation\u003c/strong\u003e: Hyperosmolarity triggers a cascade of inflammatory pathways involving \u003cstrong\u003eIL-1\u0026beta;\u003c/strong\u003e, \u003cstrong\u003eTNF-\u0026alpha;\u003c/strong\u003e, and \u003cstrong\u003eMMP-9\u003c/strong\u003e, ultimately leading to ocular surface damage (\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e). \u003cstrong\u003eLopez et al. (2023)\u003c/strong\u003e demonstrated a direct correlation between elevated \u003cstrong\u003eIL-1\u0026beta;\u003c/strong\u003e and tear film instability (\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e). However, the precise role of hyperosmolarity in inflammation is still debated. Some studies suggest that \u003cstrong\u003ehyperosmolarity\u003c/strong\u003e is a \u003cstrong\u003esecondary\u003c/strong\u003e consequence of inflammation rather than a primary driver. The inflammatory cascade involving \u003cstrong\u003eMMP-9\u003c/strong\u003e may be more pronounced in specific subtypes of DED. In contrast, others may exhibit a less pronounced inflammatory response, necessitating further investigation into biomarkers that can more accurately predict individual disease progression.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003e2. Environmental Factors\u003c/strong\u003e: Behavioral and environmental factors significantly exacerbate \u003cstrong\u003etear film instability\u003c/strong\u003e. Chen et al. (2023) observed a significant association between prolonged screen time (more than 6 hours per day) and \u003cstrong\u003eDED\u003c/strong\u003e prevalence, highlighting the impact of reduced blinking rates and digital device use (\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e). This finding aligns with the growing body of evidence suggesting that \u003cstrong\u003elifestyle modifications\u003c/strong\u003e, such as reducing screen time and improving blink rates, are critical in managing \u003cstrong\u003eDED\u003c/strong\u003e. Additionally, the \u003cstrong\u003eTFOS Lifestyle Report\u003c/strong\u003e (Craig et al., 2023) offers further insights into the role of environmental and lifestyle factors in \u003cstrong\u003eDED\u003c/strong\u003e, underscoring the need for personalized \u003cstrong\u003eDED\u003c/strong\u003e management strategies tailored to these factors. However, the influence of other environmental factors, such as \u003cstrong\u003eair quality\u003c/strong\u003e, \u003cstrong\u003ehumidity\u003c/strong\u003e, and \u003cstrong\u003eworkplace ergonomics\u003c/strong\u003e, should also be explored in future studies to understand better their full impact on the exacerbation of \u003cstrong\u003eDED\u003c/strong\u003e symptoms. Future research should integrate these factors alongside behavioral modifications to provide a more holistic approach to \u003cstrong\u003eDED\u003c/strong\u003e prevention and management.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eSystemic Contributors\u003c/strong\u003e: Autoimmune conditions such as \u003cstrong\u003eSj\u0026ouml;gren\u0026rsquo;s syndrome\u003c/strong\u003e, rheumatoid arthritis, thyroid disorders, and aging-related hormonal imbalances are recognized as systemic contributors to aqueous-deficient dry eye (ADDE) (\u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e). There is also emerging evidence on the role of mental health and psychiatric disorders in exacerbating DED, with \u003cstrong\u003estress\u003c/strong\u003e and \u003cstrong\u003edepression\u003c/strong\u003e being linked to poor tear production and higher disease severity. Future research should investigate the interrelationship between mental health and DED to improve integrated care approaches.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec21\" class=\"Section2\"\u003e\n\u003ch2\u003e4.2 Advances in Diagnostics\u003c/h2\u003e\n\u003cp\u003eSignificant advancements in diagnostic methodologies have improved early detection, disease classification, and treatment personalization.\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTear Break-Up Time (TBUT)\u003c/strong\u003e: \u003cstrong\u003eLin et al. (2023)\u003c/strong\u003e reported that a modified fluorescein TBUT boosted diagnostic accuracy by 15%, offering a simple yet effective tool to assess tear film instability (\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e). However, TBUT results can vary widely between clinicians and instruments, and their clinical significance in various DED subtypes still needs further clarification.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eAdvanced Imaging\u003c/strong\u003e: Techniques such as \u003cstrong\u003eoptical coherence tomography (OCT)\u003c/strong\u003e and \u003cstrong\u003emeibography\u003c/strong\u003e provide detailed visualization of tear meniscus volume, meibomian gland structure, and lipid layer integrity (\u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e25\u003c/span\u003e). These tools are particularly beneficial for detecting MGD and assessing disease severity; however, their cost and availability remain barriers to widespread adoption in specific clinical settings.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eBiomarker Testing\u003c/strong\u003e: Biomarkers such as \u003cstrong\u003eMMP-9\u003c/strong\u003e and \u003cstrong\u003eIL-1\u0026beta;\u003c/strong\u003e allow objective evaluation of ocular surface inflammation. \u003cstrong\u003eChen et al. (2023)\u003c/strong\u003e demonstrated a strong correlation between elevated \u003cstrong\u003eMMP-9\u003c/strong\u003e levels and the severity of clinical DED (\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e). While promising, further studies are needed to validate these biomarkers across diverse populations and disease stages.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eArtificial Intelligence (AI) and Machine Learning\u003c/strong\u003e: \u003cstrong\u003eAmouei Sheshkal et al. (2024)\u003c/strong\u003e integrated AI with metabolomics data to classify DED with high accuracy, advancing the development of personalized diagnostics (\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e). AI-based tools hold promise for precision medicine, though validation across larger cohorts is still required. Moreover, the integration of AI into clinical practice will face regulatory, technical, and financial hurdles that need to be addressed.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec22\" class=\"Section2\"\u003e\n\u003ch2\u003e4.3 Emerging Therapies\u003c/h2\u003e\n\u003cp\u003eRecent therapeutic advancements target specific mechanisms of DED, addressing both aqueous-deficient and evaporative subtypes of the condition.\u003c/p\u003e\n\u003cdiv id=\"Sec23\" class=\"Section3\"\u003e\n\u003ch2\u003e4.3.1 Pharmacological Therapies\u003c/h2\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTyrvaya\u0026reg; (Varenicline Nasal Spray)\u003c/strong\u003e: Approved for aqueous-deficient DED, Tyrvaya stimulates parasympathetic pathways to promote tear production. \u003cstrong\u003eFrampton (2022)\u003c/strong\u003e demonstrated significant improvements in tear volume within four weeks (\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e). However, patient discomfort associated with nasal delivery remains a limitation, highlighting the need for more comfortable delivery methods for patients. The clinical translation of \u003cstrong\u003eTyrvaya\u003c/strong\u003e could substantially improve treatment adherence; however, its real-world application may be limited by patient preferences and accessibility concerns.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eNOV03\u003c/strong\u003e: Lipid layer stabilizers such as \u003cstrong\u003eNOV03\u003c/strong\u003e target meibomian gland dysfunction, reducing tear evaporation and improving lipid layer quality. \u003cstrong\u003eTauber et al. (2023)\u003c/strong\u003e highlighted NOV03's efficacy in stabilizing the tear film and alleviating symptoms of evaporative DED (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e). While promising, the \u003cstrong\u003ecost\u003c/strong\u003e of these therapies and their long-term effectiveness remain to be fully evaluated. \u003cstrong\u003eNOV03\u003c/strong\u003e could offer a significant advancement in managing \u003cstrong\u003eevaporative dry eye\u003c/strong\u003e, but its real-world accessibility will need to be addressed, especially for patients in low-resource settings.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec24\" class=\"Section3\"\u003e\n\u003ch2\u003e4.3.2 Regenerative Therapies\u003c/h2\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eMesenchymal Stem Cell (MSC) Therapy\u003c/strong\u003e: MSC therapies have shown potential for restoring corneal integrity and stabilizing the tear film in severe DED cases. \u003cstrong\u003eKato et al. (2023)\u003c/strong\u003e reported enhanced tear production and ocular surface repair following MSC administration (\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e). However, \u003cstrong\u003eregulatory hurdles\u003c/strong\u003e and \u003cstrong\u003elong-term safety concerns\u003c/strong\u003e hinder the widespread use of these therapies. Clinically, \u003cstrong\u003eMSC therapy\u003c/strong\u003e could be a breakthrough for patients with severe DED; however, its high costs and limited availability may restrict its use in clinical practice.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec25\" class=\"Section3\"\u003e\n\u003ch2\u003e4.3.3 Device-Based Interventions\u003c/h2\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eLipiFlow Thermal Pulsation\u003c/strong\u003e: \u003cstrong\u003eLipiFlow\u003c/strong\u003e mechanically clears blocked meibomian glands, enhancing lipid secretion and improving tear stability. \u003cstrong\u003eTauber et al. (2023)\u003c/strong\u003e demonstrated a significant improvement in lipid layer thickness among patients undergoing LipiFlow therapy (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e). Despite its effectiveness, the \u003cstrong\u003ecost\u003c/strong\u003e and \u003cstrong\u003eavailability\u003c/strong\u003e of LipiFlow may limit its broader application. Clinically, \u003cstrong\u003eLipiFlow\u003c/strong\u003e can improve the quality of life for patients with \u003cstrong\u003eMGD\u003c/strong\u003e; however, its \u003cstrong\u003ehigh cost\u003c/strong\u003e presents a barrier to widespread adoption, particularly in resource-constrained healthcare settings.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePROSE Lenses\u003c/strong\u003e: \u003cstrong\u003eProsthetic Replacement of the Ocular Surface Ecosystem (PROSE)\u003c/strong\u003e lenses provide mechanical protection and drug delivery for severe DED cases. \u003cstrong\u003eBostonSight (2024)\u003c/strong\u003e reported improved corneal healing and symptom relief in refractory DED patients (\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e). However, high costs and limited accessibility remain barriers to widespread adoption. \u003cstrong\u003ePROSE lenses\u003c/strong\u003e show great promise for \u003cstrong\u003esevere DED\u003c/strong\u003e cases, but their \u003cstrong\u003ereal-world cost\u003c/strong\u003e and the lack of reimbursement may hinder patient access, necessitating policy interventions to reduce these barriers.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec26\" class=\"Section3\"\u003e\n\u003ch2\u003e4.3.4 Nutritional and Lifestyle Interventions\u003c/h2\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eOmega-3 Fatty Acids\u003c/strong\u003e: Nutritional interventions, particularly \u003cstrong\u003eOmega-3 supplementation\u003c/strong\u003e, have shown mixed results in reducing tear evaporation and ocular inflammation. \u003cstrong\u003eLi et al. (2023)\u003c/strong\u003e emphasized the need for further research to determine patient-specific benefits (\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e). While promising in some instances, the results of Omega-3 supplementation are inconsistent, and further studies are needed to understand the optimal dosage and treatment duration.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eBehavioral Modifications\u003c/strong\u003e: Reducing screen time, practicing regular blinking, and optimizing environmental factors (e.g., controlling humidity) remain essential for preventing and managing \u003cstrong\u003eDED\u003c/strong\u003e symptoms. According to the \u003cstrong\u003eTFOS Lifestyle Report\u003c/strong\u003e (Craig et al., 2023), \u003cstrong\u003ebehavioral modifications\u003c/strong\u003e such as \u003cstrong\u003ereducing prolonged screen exposure\u003c/strong\u003e and \u003cstrong\u003eimproving blink frequency\u003c/strong\u003e are pivotal in mitigating \u003cstrong\u003eDED\u003c/strong\u003e risk. Public health campaigns that focus on these lifestyle changes, such as encouraging regular breaks from digital devices and promoting proper ergonomics, could play a critical role in \u003cstrong\u003eDED prevention\u003c/strong\u003e. Increasing awareness about screen-time management and proper blinking habits could help mitigate \u003cstrong\u003eDED\u003c/strong\u003e risks, especially among younger populations who are heavily engaged with digital devices. Moreover, \u003cstrong\u003eenvironmental optimization\u003c/strong\u003e, such as enhancing workplace ergonomics and controlling indoor air quality, should also be emphasized in \u003cstrong\u003eDED\u003c/strong\u003e prevention strategies, as these factors can exacerbate symptoms.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec27\" class=\"Section2\"\u003e\n\u003ch2\u003e4.4. Challenges and Future Directions\u003c/h2\u003e\n\u003cp\u003eDespite significant progress, several challenges remain in the management and treatment of \u003cstrong\u003eDry Eye Disease (DED)\u003c/strong\u003e:\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHigh Costs and Limited Accessibility\u003c/strong\u003e: Advanced therapies, such as \u003cstrong\u003ePROSE lenses\u003c/strong\u003e, \u003cstrong\u003eNOV03\u003c/strong\u003e, and \u003cstrong\u003emesenchymal stem cell (MSC)\u003c/strong\u003e treatments, remain costly and often inaccessible in low-resource settings. To facilitate \u003cstrong\u003eglobal implementation\u003c/strong\u003e, it is crucial to enhance the \u003cstrong\u003eaffordability\u003c/strong\u003e and \u003cstrong\u003eaccessibility\u003c/strong\u003e of these treatments. \u003cstrong\u003ePolicy solutions\u003c/strong\u003e and \u003cstrong\u003etelemedicine interventions\u003c/strong\u003e should be explored to reduce treatment costs and expand access to effective therapies, especially for underserved populations. For example, \u003cstrong\u003eHycoSan Shield\u003c/strong\u003e, a more affordable option for \u003cstrong\u003eDED\u003c/strong\u003e management, has become widely available in many countries, providing a more accessible solution for patients at various price points.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eLong-Term Data Gaps\u003c/strong\u003e: Many emerging therapies, including \u003cstrong\u003eTyrvaya\u003c/strong\u003e, \u003cstrong\u003eNOV03\u003c/strong\u003e, and \u003cstrong\u003eMSC therapy\u003c/strong\u003e, still lack comprehensive \u003cstrong\u003elong-term efficacy\u003c/strong\u003e and \u003cstrong\u003esafety data\u003c/strong\u003e. Extended clinical trials are necessary to assess the sustained benefits and risks of these treatments. Long-term studies are crucial for guiding clinical practice and providing more robust evidence on the \u003cstrong\u003esafety\u003c/strong\u003e and \u003cstrong\u003edurability\u003c/strong\u003e of these interventions, ensuring they can be confidently recommended for \u003cstrong\u003ewidespread clinical use\u003c/strong\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePersonalized Medicine\u003c/strong\u003e: Given the \u003cstrong\u003eheterogeneity\u003c/strong\u003e of \u003cstrong\u003eDED\u003c/strong\u003e, individualized treatment approaches tailored to disease subtype, \u003cstrong\u003ebiomarkers\u003c/strong\u003e, and \u003cstrong\u003epatient-specific factors\u003c/strong\u003e are necessary. Emerging \u003cstrong\u003eAI-driven diagnostics\u003c/strong\u003e may play a crucial role in advancing \u003cstrong\u003eprecision medicine\u003c/strong\u003e by enabling clinicians to tailor treatments to the unique characteristics of each patient's disease. This personalized approach will be crucial for improving treatment outcomes and optimizing the management of \u003cstrong\u003eDED\u003c/strong\u003e.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePublic Awareness\u003c/strong\u003e: Behavioral and environmental modifications are crucial to preventing \u003cstrong\u003eDED\u003c/strong\u003e. Public awareness campaigns focused on \u003cstrong\u003escreen-time management\u003c/strong\u003e, \u003cstrong\u003eblinking habits\u003c/strong\u003e, and \u003cstrong\u003eenvironmental optimization\u003c/strong\u003e could significantly mitigate the disease burden. \u003cstrong\u003ePublic health initiatives\u003c/strong\u003e targeting lifestyle changes and preventive measures should be prioritized to address the increasing prevalence of \u003cstrong\u003eDED\u003c/strong\u003e, particularly among younger populations who are heavily engaged with digital devices. Additionally, educating the general public about the importance of \u003cstrong\u003eergonomics\u003c/strong\u003e, \u003cstrong\u003eindoor air quality\u003c/strong\u003e, and \u003cstrong\u003eproper hydration\u003c/strong\u003e could help reduce the incidence of \u003cstrong\u003eDED\u003c/strong\u003e across various demographics.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec28\" class=\"Section2\"\u003e\n\u003ch2\u003e4.5 Summary of Key Findings\u003c/h2\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePathophysiology\u003c/strong\u003e: \u003cstrong\u003eHyperosmolarity\u003c/strong\u003e, \u003cstrong\u003einflammation\u003c/strong\u003e, and \u003cstrong\u003eMeibomian Gland Dysfunction (MGD)\u003c/strong\u003e are key contributors to \u003cstrong\u003etear film instability\u003c/strong\u003e and ocular surface damage. These factors remain central to the pathophysiology of \u003cstrong\u003eDry Eye Disease (DED)\u003c/strong\u003e, as highlighted in recent reviews and studies (\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eDiagnostics\u003c/strong\u003e: Advancements in diagnostic methods, including \u003cstrong\u003efluorescein TBUT\u003c/strong\u003e, \u003cstrong\u003eOCT imaging\u003c/strong\u003e, \u003cstrong\u003ebiomarker analysis\u003c/strong\u003e, and \u003cstrong\u003eAI-driven tools\u003c/strong\u003e, have significantly enhanced diagnostic accuracy for \u003cstrong\u003eDED\u003c/strong\u003e. These tools allow for more precise and early identification of the disease, ultimately improving treatment outcomes (\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTherapies\u003c/strong\u003e: Emerging treatments, such as \u003cstrong\u003eTyrvaya\u003c/strong\u003e nasal spray, \u003cstrong\u003eNOV03 lipid stabilizer\u003c/strong\u003e, \u003cstrong\u003emesenchymal stem cell (MSC)\u003c/strong\u003e therapy, and \u003cstrong\u003ePROSE lenses\u003c/strong\u003e, offer promising solutions for \u003cstrong\u003eDED\u003c/strong\u003e management. However, challenges related to \u003cstrong\u003ecost\u003c/strong\u003e, \u003cstrong\u003eaccessibility\u003c/strong\u003e, and the \u003cstrong\u003elong-term validation\u003c/strong\u003e of these therapies need to be addressed before widespread implementation (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eChallenges\u003c/strong\u003e: Key priorities for future research include addressing the \u003cstrong\u003ehigh costs\u003c/strong\u003e of treatments, improving \u003cstrong\u003eaccessibility\u003c/strong\u003e, and further developing \u003cstrong\u003epersonalized medicine\u003c/strong\u003e approaches. The integration of \u003cstrong\u003eAI\u003c/strong\u003e in diagnostics and the tailoring of treatments based on individual patient characteristics are essential steps to enhance the effectiveness of \u003cstrong\u003eDED\u003c/strong\u003e management (\u003cspan class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThis diagram summarizes the pathophysiology of DED, including tear film instability, hyperosmolarity, and inflammation. It highlights advanced diagnostic tools, such as fluorescein TBUT, OCT, meibography, and biomarker analysis, as well as emerging therapies, including Tyrvaya nasal spray, NOV03 lipid stabilizer, LipiFlow thermal pulsation therapy, stem cell therapy, and PROSE scleral lenses.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003cdiv class=\"colspec\" align=\"left\"\u003e\u0026nbsp;\u003c/div\u003e\n\u003ctable id=\"Tab2\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eSummary of Key Findings in the Discussion Section\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eAspect\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eKey Findings\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eAdvancements\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eChallenges\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003ePathophysiology\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- DED is driven by \u003cstrong\u003etear film instability\u003c/strong\u003e, \u003cstrong\u003ehyperosmolarity\u003c/strong\u003e, inflammation, and MGD.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Identification of key inflammatory mediators (IL-1\u0026beta;, TNF-\u0026alpha;, MMP-9).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Incomplete understanding of precise molecular pathways in DED.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Hyperosmolarity triggers inflammatory cytokine release, worsening ocular damage.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Role of meibomian gland dysfunction (MGD) in evaporative DED clarified.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Lack of direct therapies addressing hyperosmolarity.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eDiagnostics\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Conventional tests (TBUT, Schirmer\u0026rsquo;s) remain widely used.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- \u003cstrong\u003eFluorescein TBUT\u003c/strong\u003e improves accuracy in assessing tear film instability (\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- High variability in results from Schirmer\u0026rsquo;s test across studies.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- \u003cstrong\u003eAdvanced imaging\u003c/strong\u003e (OCT, meibography) provides precise visualization of tear film and glands.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- \u003cstrong\u003eBiomarker testing\u003c/strong\u003e (MMP-9, IL-1\u0026beta;) correlates inflammation with severity (\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eBiomarker Testing\u003c/strong\u003e: \u003cstrong\u003eInflammaDry\u003c/strong\u003e for MMP-9 is widely available, but its high cost limits accessibility in clinical practice (\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- AI-based diagnostic models enhance accuracy (\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e21\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- AI integration with metabolomics achieves high diagnostic precision (\u003cspan class=\"CitationRef\"\u003e21\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Machine learning models require large datasets for validation.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacological Therapies\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- \u003cstrong\u003eTyrvaya\u0026reg; (varenicline nasal spray)\u003c/strong\u003e stimulates tear production via nasal pathways.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Novel mechanism targets parasympathetic pathways (\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Limited to aqueous-deficient DED and may cause nasal discomfort (\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- \u003cstrong\u003eNOV03\u003c/strong\u003e stabilizes the tear lipid layer in evaporative DED (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Effective treatment for meibomian gland dysfunction.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eBiomarker Testing\u003c/strong\u003e: \u003cstrong\u003eInflammaDry\u003c/strong\u003e for MMP-9 is widely available and is now relatively affordable, but there are still limitations in terms of \u003cstrong\u003elong-term safety data\u003c/strong\u003e and \u003cstrong\u003ewidespread clinical accessibility\u003c/strong\u003e (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eRegenerative Therapies\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- \u003cstrong\u003eMesenchymal stem cell (MSC) therapy\u003c/strong\u003e shows promise in corneal regeneration.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Improves tear production and surface repair in severe DED (\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Requires long-term studies to evaluate safety, efficacy, and regulatory approval (\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eDevice-Based Therapies\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- \u003cstrong\u003eLipiFlow\u0026reg;\u003c/strong\u003e unclogs meibomian glands, improving lipid secretion.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Thermal pulsation therapy effectively treats evaporative DED (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Accessibility and affordability remain challenges for widespread adoption.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- \u003cstrong\u003ePROSE scleral lenses\u003c/strong\u003e deliver drugs and improve surface healing (\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Effective in severe or refractory DED cases (\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- High cost and limited access in low-resource settings (\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eNutritional Interventions\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Omega-3 supplementation shows mixed results in reducing tear evaporation.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Potential anti-inflammatory benefits in select patients (\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e28\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Inconsistencies in study designs limit definitive conclusions (\u003cspan class=\"CitationRef\"\u003e28\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eInflammation Management\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Inflammatory cytokines (IL-1\u0026beta;, TNF-\u0026alpha;) play a central role in DED progression.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Immunotherapy reduces inflammation and promotes tear production (\u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eCiclosporin\u003c/strong\u003e has been used in \u003cstrong\u003eDED\u003c/strong\u003e treatment for some time, and a substantial body of data exists on its efficacy and safety. However, despite its long-standing use, there is limited \u003cstrong\u003eclinical trial data\u003c/strong\u003e on its \u003cstrong\u003elong-term outcomes\u003c/strong\u003e and \u003cstrong\u003esafety\u003c/strong\u003e (\u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eChallenges and Gaps\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- DED remains underdiagnosed and undertreated globally.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Innovations in imaging, biomarkers, and AI tools improve diagnostic precision.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- High costs limit access to advanced diagnostics and therapies.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- New treatments like Tyrvaya and NOV03 show short-term efficacy.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Emerging therapies such as stem cells and scleral lenses address severe cases.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Further research required to evaluate long-term efficacy, affordability, and accessibility.\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003ePersonalized Medicine\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Heterogeneity in DED requires individualized treatment approaches.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- AI tools and biomarker analysis enable personalized diagnostics and therapy.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Current guidelines lack specificity for individualized treatment plans (\u003cspan class=\"CitationRef\"\u003e9\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eEnvironmental and Lifestyle\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Prolonged screen time exacerbates DED symptoms (\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Behavioral interventions (screen breaks, humidifiers) help reduce symptoms.\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e- Limited public awareness about preventive strategies and environmental modifications (\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u003cstrong\u003eSummary of the Table\u003c/strong\u003e\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePathophysiology\u003c/strong\u003e: Advances in identifying inflammatory mediators and the role of tear film instability have improved understanding of DED. However, therapies targeting hyperosmolarity and inflammation remain limited.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eDiagnostics\u003c/strong\u003e: Innovations such as fluorescein TBUT, advanced imaging techniques (e.g., OCT and meibography), and AI-driven models have significantly improved the diagnostic precision of DED. However, several challenges persist in clinical practice. High costs remain a significant barrier to the widespread adoption of advanced imaging technologies and AI models. Moreover, there is variability in results between different diagnostic tools and between practitioners, which can complicate standardization across clinics. Limited availability of these technologies in routine clinical settings, due to infrastructure limitations and financial constraints, further hinders their broader implementation. As a result, while these innovations show great promise, their integration into clinical practice requires overcoming these challenges to ensure consistent and accessible DED management.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eTherapies: (\u003c/strong\u003eFig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003e\u003cstrong\u003e)\u003c/strong\u003e\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003ePharmacological treatments\u003c/strong\u003e, such as Tyrvaya\u0026reg; (varenicline nasal spray) and NOV03 (lipid stabilizer), show promising outcomes, particularly for aqueous-deficient and evaporative DED. Tyrvaya\u0026reg; has demonstrated improvements in tear production, offering a novel mechanism of action through nasal stimulation, while NOV03 has proven effective in stabilizing the lipid layer in MGD-related DED. Despite these advances, challenges remain, including the cost of these treatments and the lack of long-term safety data to support their sustained use (\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e). These factors limit their broader application, particularly in low-resource settings where affordability is a significant concern. Future studies are crucial for validating the long-term efficacy and safety of these therapies, as well as for identifying strategies to enhance accessibility.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eRegenerative therapies\u003c/strong\u003e (MSCs) and \u003cstrong\u003edevice-based treatments\u003c/strong\u003e (LipiFlow, PROSE lenses) address severe cases but face challenges related to accessibility and affordability.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eNutritional interventions\u003c/strong\u003e yield mixed results, underscoring the need for personalized recommendations.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eChallenges and Future Directions\u003c/strong\u003e: Gaps in long-term efficacy data, affordability issues, and the need for personalized medicine approaches pose significant challenges\u0026mdash;innovations in AI, biomarkers, and immunotherapies present opportunities to improve outcomes.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eEnvironmental and Lifestyle Factors\u003c/strong\u003e: Addressing behavioral risk factors, such as screen exposure, remains critical for prevention and management.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e"},{"header":"6. Conclusion","content":"\u003cp\u003eThe management of Dry Eye Disease has improved significantly with advances in diagnostics and therapeutic options. Understanding the heterogeneity of DED is critical for developing personalized, targeted treatments. Future research should focus on the long-term efficacy, affordability, and accessibility of novel interventions, while also emphasizing preventive strategies to mitigate environmental and lifestyle risks.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eConflict of interest\u003c/h2\u003e\n\u003cp\u003e\u0026quot;Author declares no conflict of interest.\u0026quot;\u003c/p\u003e\n\u003ch2\u003e7.\u0026nbsp;Author Contributions Statement\u003c/h2\u003e\n\u003cul\u003e\n \u003cli\u003e\u003cstrong\u003eArian Ghannadi Karimi\u003c/strong\u003e: Conceptualization, methodology, formal analysis, writing \u0026ndash; original draft, writing \u0026ndash; review and editing, supervision, co-corresponding author.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eAmir Ershad Tavakolian\u003c/strong\u003e: Conceptualization, methodology, formal analysis, writing, review and editing, project administration.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eDarya Ipchian\u003c/strong\u003e: Data curation, formal analysis, writing, review, and editing.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eFatemeh Ghasemi Ghale Bahmani\u003c/strong\u003e: Data curation, formal analysis, writing, review, and editing.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eArsalan Jamali pour Soofi\u003c/strong\u003e: Methodology, data curation, writing, review, and editing.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eManagol Kayyal\u003c/strong\u003e: Methodology, writing, review, and editing.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eAmirreza Geranfar\u003c/strong\u003e: Data curation, writing, review, and editing.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eSahand Kamali\u003c/strong\u003e: Data curation, writing, review, and editing.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eLeili Noroozi Mollaei\u003c/strong\u003e: Data curation, writing, review, and editing.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eAll authors have read and approved the final manuscript. \u003cstrong\u003eArian Ghannadi Karimi\u003c/strong\u003e and \u003cstrong\u003eAmir Ershad Tavakolian\u003c/strong\u003e are co-corresponding authors.\u003c/p\u003e\n\u003ch2\u003e8.\u0026nbsp;Acknowledgement\u003c/h2\u003e\n\u003cp\u003eWe want to express our sincere gratitude to all those who have contributed to the successful completion of this comprehensive review on \u003cstrong\u003eDry Eye Disease (DED)\u003c/strong\u003e. First, we would like to thank our supervisor, \u003cstrong\u003eDr. Bahman Inanlou\u003c/strong\u003e, for their invaluable guidance, support, and encouragement throughout the research process. Their expertise and insightful suggestions greatly enhanced the depth of this work. A special thank you goes to \u003cstrong\u003ePromed Club\u003c/strong\u003e for their contributions, particularly in providing insights into recent advances in diagnostics and therapeutic options for DED. Their research and discussions have been a crucial component of this review. Lastly, we would like to acknowledge our \u003cstrong\u003efamily and friends\u003c/strong\u003e for their unwavering support and encouragement, which helped us stay focused and motivated throughout this work. This review is dedicated to all those affected by \u003cstrong\u003eDry Eye Disease\u003c/strong\u003e, and we hope that the findings presented will contribute to advancing the understanding and treatment of this debilitating condition.\u003c/p\u003e\n\u003ch2\u003e\u003cstrong\u003e9. Funding\u003c/strong\u003e\u003c/h2\u003e\n\u003cp\u003eThe authors declare that no funding was received for this research\u003c/p\u003e\n\u003ch2\u003e\u003cstrong\u003e10.\u0026nbsp;\u003c/strong\u003eEthics, Consent to Participate, and Consent to Publish declarations\u003c/h2\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eCraig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Report: Executive summary. Ocul Surf. 2017;15(3):575\u0026ndash;628.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChen Q, Liu G, Wu L, et al. Impact of screen time on dry eye disease: A cross-sectional study. Br J Ophthalmol. 2023;107(2):257\u0026ndash;263.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMathews PM, Ramulu PY, Swenor BS, et al. Risk factors associated with dry eye syndrome in older adults: A multi-center observational study. Am J Ophthalmol. 2022;236:45 53.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLin H, Li W, Xie Z, et al. Fluorescein tear break-up time in dry eye disease: A modified approach. Eye Vis. 2023;10:9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTauber J, Berdy GJ, Wirta DL, et al. NOV03 for the treatment of dry eye disease associated with meibomian gland dysfunction: Results from the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516\u0026ndash;524.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFrampton JE. Varenicline solution nasal spray (Tyrvaya\u0026reg;): A review in dry eye disease. Drugs. 2022;82(14):1481\u0026ndash;1488.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: A comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311\u0026ndash;318.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHuang D, Li Z. Multidimensional immunotherapy for dry eye disease: Current status and future directions. Front Ophthalmol. 2024;4(1):1449283.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAmerican Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Dry eye syndrome. AAO. 2023.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBostonSight. BostonSight PROSE treatment and scleral lenses: Drug delivery system in severe dry eye. Ophthalmology Times. 2024.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChen Y, Jiang Z, Wang Y, et al. Correlation of biomarkers IL-1β and MMP-9 with dry eye disease severity. J Clin Med. 2023; 12(5): 1316.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePower A, Yeu E, Cason T, et al. Clinical trials for dry eye disease: Advances in treatment and outcomes. Clin Trials J. 2023;12(1):40\u0026ndash;48.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePacker M, Donnenfeld E. Canalicular gels as a sustained treatment for persistent dry eye disease. Ophthalmology Times. 2024.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWilson SE. Inflammatory mechanisms in dry eye disease. Cornea. 2022;41(Suppl 1):S25\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDana R, Mehra D, Martin T, et al. Estimated prevalence and incidence of dry eye disease in the United States: A retrospective analysis. Am J Ophthalmol. 2019;202:47 54.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHakim FE, Farooq AV. Dry eye disease: An update on clinical understanding and management. JAMA. 2022;327(5):478\u0026ndash;479.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKothapalli T, Lewis JB, Venkataraman S. Tracking tear film lipid layer dynamics using computational models. J Ocul Biol. 2022;33(2):112\u0026ndash;118.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi W, Li Z, Xie H, et al. Nutritional supplementation for dry eye: A meta-analysis of omega-3 fatty acids. Nutr J. 2023;22(1):7026.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLopez A, Taylor D, Martin T. Role of cytokines in tear film composition and dry eye severity. Exp Eye Res. 2023;217:108906.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAmouei Sheshkal F, Anvari P, Salami H, et al. Machine learning and metabolomics analysis for the diagnosis of dry eye disease. Sci Rep. 2024;14(3):231\u0026ndash;242.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBrahim N, Tsai P, Lee H, et al. Advances in ocular surface mapping for grading dry eye severity. J Biomed Optics. 2024;29(1):1235\u0026ndash;1245.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDriscoll TA, Nichols JJ, Nichols KK. Quantitative modeling of tear film breakup dynamics. Math Med Biol. 2022;39(2):35\u0026ndash;48.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKarpecki P, Holland EJ. Emerging therapies for meibomian gland dysfunction and evaporative dry eye. Review of Optometry. 2023.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBostonSight Research Team. Drug delivery via scleral lenses: A novel solution for severe DED. J Ocul Pharmacol Ther. 2023;39(6):420\u0026ndash;430.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi Y, Xu Y, Zhao H. The link between dry eye disease and psychiatric disorders: A population-based study. Psychiatry Res. 2023;317:114787.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKato T, Li R, Sakamoto M. Stem cell therapy for corneal regeneration in dry eye disease: A systematic review. Stem Cell Res Ther. 2023;14(8):281.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWith Power Clinical Trials. Dry Eye Disease Clinical Trials: Pipeline Review 2024. Clin Trials Rev. 2024.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLopez I, Chen J, Roberts H, et al. Advances in tear film lipid layer imaging: New tools for clinical practice. J Ocul Imaging. 2023;12(3):77\u0026ndash;85.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHealthline Editorial Team. Current therapies for dry eye disease: Emerging treatments and updates. Healthline. 2024.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eModern Optometry. Dry eye pipeline: New drugs and technologies to watch. Modern Optometry. 2023.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-6275992/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6275992/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eDry Eye Disease (DED) is a multifactorial ocular condition characterized by tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. DED impacts millions worldwide, leading to symptoms such as irritation, dryness, and visual disturbances. In recent years, advances in diagnostics, treatment modalities, and understanding of DED pathophysiology have transformed its clinical management. This review examines the current evidence (2022\u0026ndash;2024), with a focus on etiology, diagnostic tools, and emerging therapeutic options, while highlighting knowledge gaps and outlining future research directions.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003e\u003c/p\u003e","manuscriptTitle":"A Comprehensive Review of Dry Eye Disease: Recent Advances and Future Directions","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-07-14 11:52:07","doi":"10.21203/rs.3.rs-6275992/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"9922613f-2f79-4d8e-825d-70702a2789b6","owner":[],"postedDate":"July 14th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-11-19T10:08:15+00:00","versionOfRecord":[],"versionCreatedAt":"2025-07-14 11:52:07","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6275992","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6275992","identity":"rs-6275992","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}